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SOMATOSTATIN RECEPTOR 2 REGULATION BY C-TERMINAL MOTIFS AND 
PDZ DOMAIN PROTEINS 
 
Courtney Olsen, B.A. 
Advisory Professor: Agnes Schonbrunn, Ph.D. 
 
Somatostatin receptor 2 (sst2) is a Gi-coupled G-protein coupled receptor that 
mediates many of somatostatin’s neuroendocrine actions. Sst2 is a clinically 
important GPCR as it is the drug target of somatostatin analogs such as octreotide, 
lanreotide, and pasireotide. Treatment with these agonists is the main medical 
approach to controlling excessive hormone secretion from neuroendocrine tumors. 
Activation of sst2 decreases hormone secretion by inhibiting cAMP production and 
decreasing intracellular calcium concentrations. In addition, treatment with 
somatostatin analogs has been shown to decrease tumor growth. Unfortunately, 
many patients will fail to respond to somatostatin analogs despite sst2 being present 
on their tumors. Understanding the signaling, trafficking, and regulation of sst2 is 
crucial to determine why many patients fail to respond to these agonists. As 
Postsynaptic density protein/Discs large-1/Zona occludens-1 (PDZ) domain 
interactions often regulate the trafficking and signaling potential of other GPCRs, we 
examined the role of the sst2 PDZ ligand and additional C-terminal residues in 
controlling its intracellular trafficking, signaling, and regulation. We determined that 
sst2 traffics from early endosomes to late endosomes and then on to the trans-golgi 
network (TGN). Trafficking from late endosomes to the TGN is dependent upon an 
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intact C-terminal tail and the retromer complex of endosomal coat proteins. 
Additionally, removing either 3 or 10 C-terminal amino acids from sst2 alters the 
pathway through which sst2 recycles to the plasma membrane. We also determined 
that the expression of SHANK3, a PDZ domain containing protein, could alter the 
plasma membrane expression of sst2 indicating an important role in sst2 regulation. 
Overall, our results indicate that sst2 trafficking and regulation depends upon an 
intact PDZ ligand and C-terminal tail. 	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Chapter 1 
Introduction 
 
1.1 Somatostatin Receptors 
The family of somatostatin receptors was originally discovered in pituitary 
cells and was subsequently found to be present throughout the endocrine, 
neuroendocrine, and gastrointestinal (GI) system and act to negatively regulate 
hormone secretion(1-4). Additionally, they are present in the central and peripheral 
nervous systems and act to regulate cognitive, motor, and sensory functions as well 
as pain transmission(5, 6). Physiologically, they play important roles in inhibiting a 
wide range of hormone secretion including growth hormone, insulin, and glucagon. 
These receptors also inhibit GI and pancreatic exocrine secretion(2, 3, 7).  
The family of somatostatin receptors consists of five members, part of the 
larger family of G protein coupled receptors (GPCRs), and exert their actions mainly 
through coupling to Gi and Go proteins, members of the family of heterotrimeric 
guanine-nucleotide binding proteins (G-proteins), to inhibit cyclic adenosine 
monophosphate (cAMP)(8-11). Somatostatin receptors have two endogenous 
ligands that exist as cyclic peptide products, Somatostatin 14 (SS14) and 
Somatostatin 28 (SS28) generated from a 116 amino acid precursor product. Both 
ligands bind to all 5 family members with similar high affinity(3). Along with their 
importance in endogenous physiological functions, somatostatin receptors play an 
important role clinically as they are highly expressed on the surface of many 
neuroendocrine tumors (NETs)(1, 12-14). Somatostatin analogs, which act by 
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activating somatostatin receptors, were developed to control the high levels of 
hormones secreted from these tumors(15). Octreotide is the main drug in this class 
and acts by activating sst2 to both inhibit hormone secretion and slow tumor growth 
and as such sst2 is a crucial receptor for the overall treatment of NETs(2, 16-18). 
 
1.2 Neuroendocrine Tumors (NETs) 
NETs are tumors that arise from endocrine tissues such as pituitary and 
pancreas as well as the diffuse neuroendocrine system(19). These tumors can be 
functional, meaning that they secrete hormones, or non-functional, and benign and 
malignant tumors fall into both categories. The cell type of origin determines the 
hormone secreted and over 15 neuroendocrine cell types secreting different 
hormones have been identified(20-22). One of the most difficult aspects of managing 
these tumors is the hormonal hyper-secretion leading to different endocrine 
syndromes (Fig 1)(19, 23). Although certain NETs are more likely to be malignant, 
tumors arising from any of the different cell types can be either benign or malignant 
and treatment varies depending on the aggressiveness of the tumor(19, 22, 24, 25). 
 NETs are grouped into 3 basics types, those that arise from the pituitary, 
those that arise from the endocrine pancreas, and those that occur in the diffuse 
gastrointestinal and bronchial neuroendocrine tissue.  Pituitary tumors can secrete 
growth hormone (GH), adrenocorticotrophic hormone (ACTH), prolactin, or 
thyrotropin stimulating hormone (TSH)(26, 27). Those from the endocrine pancreas 
can secrete insulin, glucagon, gastrin, vasoactive intestinal peptide (VIP), or 
somatostatin(28). GI and bronchial neuroendocrine tumors tend to secrete serotonin 
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and other vasoactive hormones including histamine, bradykinin, and other members 
of the tachykinin family of peptides(29).  
 
 
 
 
 
 
 
Figure 1. Neuroendocrine Tumors. The main sites for neuroendocrine tumors 
include the pituitary, bronchial tree, the pancreas, and the gastrointestinal 
system. These tumors can be nonfunctional or functional depending on if they 
secrete hormones. Functional tumors can secrete a variety of hormones 
depending on their tissue of origin as listed above and can cause symptoms 
ranging from debilitating to deadly.  
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 NETs can be sporadic or associated with a genetic syndrome and numerous 
drivers of tumorigenesis have been implicated. Mutations in GNAS and mutations 
and amplifications of GPR101, a Gs-coupled GPCR, can lead to somatotroph 
tumors implicating cAMP as a driver of both tumorigenesis and GH secretion(30, 
31). Other mutations include those in AIP, MENIN, CDKN1B, PRKAR1A, and the 
genes of the succinate dehydrogenase family (SDH)(32). Patients with 
neurofibromatosis type 1 and tuberous sclerosis are also predisposed to developing 
NETs, implicating the PI3K/AKT/mTOR pathway in tumorigenesis(33). Tumors 
driven by these various mutations differ in their response to somatostatin analogs 
including octreotide(16, 34, 35). How these mutations change the response to 
somatostatin analogs is not completely clear, although there are some mechanistic 
explanations depending on the mutation. For example, treatment with octreotide 
actually increases expression of AIP leading to a poor response to treatment(35, 
36). Tumors with identifiable drivers and those that are part of genetic syndromes 
are a small percentage of the total population of neuroendocrine tumors(32). The 
drivers of neuroendocrine tumors and how they may change response to treatment, 
especially to somatostatin analogs, is still poorly understood.  
 Almost all neuroendocrine tumors, both functional and non-functional, 
express sst2 at high levels on the cells surface(37, 38). Some also express sst5, as 
well as the other somatostatin receptor subtypes(39). This is generally dependent on 
the tumor type (although not always the case), as ACTH secreting tumors of the 
pituitary, and insulinomas of the pancreas are more likely to express higher levels of 
sst5 versus GH-secreting pituitary tumors that are more likely to express high levels 
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of sst2(40). These patterns of expression help to guide appropriate therapies for the 
various different NETs.	  	  	  
1.3 Somatostatin Analogs (SA)	  
 As the half-life of SS14 and SS28 in circulation is about 1-3 min, stable 
peptides have been developed to target the family of somatostatin receptors for the 
treatment of NETs(18). Octreotide is the main medical treatment available to control 
hormone hyper-secretion from NETs. The mechanism of action is through binding to 
and activating sst2 specifically(5, 41). Octreotide is safe and effective for many 
patients, however different tumor types show different patterns of resistance. 
Patients with GH-secreting tumors causing acromegaly or gigantism tend to either 
respond or not after the initial trial of drug and about 40-50% of patients will fail to 
control their hormone hyper-secretion with octreotide(16). The mechanisms that 
regulate this response are unclear. The response to octreotide does not correlate 
with receptor mRNA levels and mutations within sst2 are rarely found within pituitary 
tumors(16, 38). Given these findings, it is likely that the resistance is derived from 
the cellular environment, meaning that either the regulation of sst2 or its ability to 
engage with its downstream signaling transduction machinery is altered. This is in 
contrast to patients with GI and pancreatic NETs that tend to lose responsiveness to 
treatment over months or years of treatment(2, 16, 42). Given the long period before 
resistance develops, the mechanism is more likely dependent on expression 
changes of sst2 or its effectors as tumors grow and develop(2). 
Additionally, lanreotide is a clinically used SA that is also an sst2 specific 
agonist(43). In addition to the inhibition of hormone secretion, both octreotide and 
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lanreotide have been shown to have anti-tumor effects separate from their effects on 
hormone secretion(44, 45). This has been shown in a series of clinical trials 
demonstrating that SAs can increase the time to progression for non-functioning 
neuroendocrine tumors(44, 46). This effect has also been shown in preclinical 
models and the mechanisms and signaling leading to these anti-tumor effects have 
yet to be fully elucidated(47). 
 Recently, an additional SA, pasireotide, was approved for use in treatment 
resistant acromegaly and Cushing’s disease. Unlike octreotide and lanreotide, 
pasireotide, also referred to as SOM230, is not an sst2 specific agonist and will 
activate both sst2 and sst5. Additionally, pasireotide acts as a biased agonist at sst2, 
meaning that it does not activate the same set of pathways as the receptor’s 
endogenous ligand, SS14(48, 49). In addition to the development of SAs for the 
treatment of neuroendocrine tumors, radiolabeled octreotide compounds are used 
for both diagnostic and therapeutic purposes in clinic. Radiolabeled octreotide allows 
for accurate localization of NETs and peptide receptor radionuclide therapy (PRRT) 
has recently become available as a treatment for sst2 positive NETs(50). 
 
1.4 Somatostatin Receptor 2 (sst2) Signaling 
 Sst2 is a GPCR that primarily couples to Gi/Go proteins to inhibit adenylate 
cyclase (AC)(8, 10, 51). The inhibition of AC and subsequent reduction of cAMP 
levels is the main mechanism through which sst2 can inhibit hormone secretion(52). 
Additionally, there are other cAMP-independent mechanisms through which sst2 can 
inhibit hormone secretion. These have been most extensively studied in GH4C1 
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cells.  GH4C1 cells were derived from a spontaneous rat somatolactotroph pituitary 
tumor and secrete GH and prolactin both at a basal level and after stimulation(53). 
The activation of Gi/Go proteins by sst2 in GH4C1 cells can activate potassium 
channels (such as G-protein gated inward rectifier) leading to membrane 
hyperpolarization. The subsequent inhibition of voltage dependent calcium channels 
due to membrane hyperpolarization causes a decrease in intracellular calcium(51, 
54, 55). Reduction of either cAMP or intracellular Ca2+ will lead to a decrease in 
hormone secretion, and together the effect is synergistic(55). The effect on K+ 
channels is pertussis toxin (PTX) sensitive, indicating the necessity of Gi/Go 
proteins, and independent of the cAMP levels, as activation of sst2 still was able to 
hyperpolarize the membrane even in the presence of a stable cAMP analog(54, 55). 
Sst2 has also been shown to regulate calcium channels directly, through direct 
inhibition, also in a PTX-dependent manner(55). These effects have been shown in 
a variety of different neuroendocrine cells lines including: other pituitary somatotroph 
cells lines such as GH12C1 and GH3 cells, AtT20 cells, a corticotroph cell line, as 
well as BON cells, a pancreatic NET cell line, and several insulinoma cell lines 
amongst others(48, 56-60). The inhibitory effects of sst2 on hormone secretion have 
also been shown using human pituitary tumor samples and are well documented 
clinically through the use of somatostatin analogs(61). 
 Activation of sst2 has long been shown to inhibit tumor growth through 
several different mechanisms including the blockade of cell cycle progression, 
indirect inhibition of the secretion of growth factors, and through the inhibition of 
angiogenesis(2, 62). Sst2 has been shown to couple to phosphotyrosine 
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phosphatases, including SHP-1, SHP-2, and PTPη as well as serine/threonine 
phosphatases including PP2A and PP2B(63-66). Coupling to phosphotyrosine 
phosphatases allows sst2 to regulate growth factor receptors and their downstream 
effectors to regulate cell cycle progression and induce apoptosis. Sst2 has also been 
shown to regulate the extracellular signal-regulated kinase/mitogen-activated protein 
kinases pathway (ERK/MAPK) although the regulation is cell type specific(48). 
Interestingly, the downstream consequences of the activation or inhibition of the 
ERK/MAPK pathway is also cell type specific. For example, activation of ERK in 
somatolactotroph cells will inhibit cells growth, opposite of the role ERK plays in 
most tissues(67-69).  Sst2 will activate the ERK pathway under certain conditions 
and inhibit it under others. The activation or inhibition of the ERK/MAPK pathway is 
also dependent upon the agonist used to stimulate sst2. Stimulation of sst2 in 
Human Embryonic Kidney (HEK293) cells leads to a transient activation of ERK and 
there is both a PTX-sensitive and PTX-insensitive component to the activation. The 
activation of the ERK/MAPK pathway in other cells, such as AR42J cells, by sst2 
has been shown to be through PTX-insensitive G-proteins such as G14. It is unclear 
what the mechanism of PTX-insensitive ERK activation is in HEK293 cells as they 
do not express G14(48). In addition to the differences seen in ERK activation in 
different cell lines, sst2 also exhibits other cell specific effects such as the ability to 
increase intracellular calcium in HEK293 cells versus inhibiting intracellular calcium 
accumulation in somatotroph cells(48, 54, 55).  
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Figure 2: Sst2 signaling in somatolactotroph cells. Sst2 signaling has been best 
characterized in somatolactotroph cell lines. Sst2 is a Gi/o coupled GPCR and acts 
to inhibit cAMP. The decrease in cAMP leads to an inhibition of hormone secretion. 
Additionally sst2 acts by activating potassium channels to hyperpolarize cells. This 
leads to an inhibition of voltage gated ion channels, a decrease in intracellular 
calcium, and the inhibition of growth hormone secretion. These pathways can act 
independently to decrease secretion and are synergistic when activated together. 
Additionally, sst2 can signal to addition pathways such as the ERK/MAPK pathway 
and through phosphotyrosine phosphatases.  
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1.4 Sst2 Regulation and Trafficking 
 Endocytosis of receptors and intracellular trafficking is a major mechanism of 
GPCR regulation(70). Following internalization, GPCRs can either be recycled to the 
plasma membrane or sorted into degradation pathways to be degraded either in 
lysosomes or by the proteasome(71). Originally thought to regulate only the duration 
of stimulation and subsequent resensitization of receptors, endocytosis has recently 
been shown to also regulate the specific signaling profile activated by GPCRs (72-
75). In vivo trafficking of sst2 has been shown in several different NET tumor types 
both by somatostatin receptor scintigraphy and through immunohistochemistry of 
octreotide treated human tumor samples(76-78). Like other GPCRs, sst2 trafficking 
is intricately regulated by numerous effectors including β-arrestin, kinases, and 
phosphatases(66, 79, 80).   
After stimulation with agonist, sst2 is rapidly phosphorylated, internalized, and 
desensitized. This has been demonstrated in a variety of cell lines(76, 81, 82).  
Stimulation with SS14 leads to rapid phosphorylation by G-protein receptor kinases 
(GRK) at numerous sites in the C-terminal tail and third intracellular loop mainly 
mediated by GRK2 and GRK3(83). Phosphorylation of sst2 has been shown to 
influence its trafficking, as phosphorylation of the threonine cluster on the C-terminal 
tail is required for β-arrestin recruitment and binding(79). Additionally, 
phosphorylation of the serine cluster in the C-terminal tail is important for 
desensitization(79). Sst2 has also been shown to be phosphorylated by PKC 
although the functional consequences of PKC phosphorylation are still unclear(83).  
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 Phosphorylation of the threonine cluster in the C-terminal tail leads to β-arrestin 
binding, the recruitment of AP1 and clathrin, and internalization into clathrin coated 
pits in a dynamin-dependent manner(79, 80). Class A GPCRs transiently interact 
with β-arrestin and class B GPCRs form stable complexes with β-arrestin during 
endocytosis. Both β-arrestin1 and β-arrestin2 are recruited to the plasma membrane 
after stimulation of sst2 and forms a stable complex with sst2 during internalization 
indicating that sst2 belongs to the class B subgroup. After endocytosis, sst2 
internalizes into early endosomes, however the trafficking pathway past this first step 
has not been well described(84). Trafficking of sst2 to the trans-golgi network (TGN) 
has been shown in both HEK293 and neuronal cell lines although neither the 
mechanism for how sst2 traffics to the TGN nor the functional consequence of this 
pathway has been demonstrated(82-85). Sst2 also can rapidly recycle to the plasma 
membrane after the removal of agonist, although it was not known which pathways 
the receptor recycles through or which proteins are required(Fig. 3)(80). Very little 
degradation of sst2 is seen after stimulation, consistent with most of the receptors 
returning to the plasma membrane after the removal of ligand(80). How sst2 traffics 
through this pathway, whether sst2 can enter multiple intracellular trafficking 
pathways, and which domains on sst2 are required for trafficking had not been 
determined prior to this study. 
While some of the phosphorylation sites in the C-terminal tail have been 
shown to be involved in trafficking, little is known about how protein-protein binding 
within the C-terminal tail regulates sst2 trafficking. Sst2 has a highly evolutionarily 
conserved class I PDZ ligand at its C-terminal tail(7). PDZ ligands are protein-protein 
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binding motifs and class I ligands are defined by having a serine or threonine in the -
2 position followed by any amino acid and a hydrophobic amino at the C-terminal 
position (S/T-X-Φ)(86). Class I PDZ ligands are present on numerous GPCRs and 
are important regulators of receptor recycling, intracellular trafficking, and receptor 
signaling through binding to PDZ domain containing proteins(86, 87). Although sst2 
has been shown to bind to three PDZ domain containing proteins, SHANK1, 
SHANK2, and PDZK1, nothing was known about the function of the sst2 PDZ 
ligand(88-91). 
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SS14$
sst2$
EE$
TGN$
Figure 3: Sst2 intracellular trafficking.  While sst2 has been shown to 
internalize after stimulation with ligand and recycle to the plasma membrane, little 
is known about its intracellular trafficking pathway. Sst2 has been shown to 
internalize into early endosomes (EE), traffic to the trans-golgi network (TGN), 
and recycle to the plasma membrane.  
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1.5 GPCR Endocytic Trafficking 
Endocytic trafficking is a major mechanism of GPCR regulation and in turn, 
GPCR trafficking is regulated by numerous mechanisms. GPCRs exhibit sequence-
dependent recycling, meaning that they require specific cytoplasmic amino acids 
sequences for proper intracellular trafficking(70, 92, 93). The sequences can bind to 
cytoplasmic adapter proteins to direct their trafficking or can be modified including 
through phosphorylation or ubiquitination to alter their intracellular fate(92, 94, 95). 
The first step in trafficking occurs immediately after stimulation with ligand and 
receptors are rapidly phosphorylated, can bind to β-arrestin, and are endocytosed in 
clathrin-coated pits(93, 96). This process is the first step in endocytic sorting as 
receptors can vary greatly in terms of their phosphorylation sites and β-arrestin 
recruitment. Additionally, some receptors internalize via clathrin-independent 
mechanisms(97, 98). After internalization, receptors are sorted along the endocytic 
pathway and many internalize into early endosomes. The early endosome has been 
shown to be a highly dynamic and regulated system that allows for sorting of diverse 
cargos including numerous different GPCRs and other membrane receptors(71, 99-
101). From the early endosome, receptors can be trafficked back to the plasma 
membrane, traffic through longer recycling pathways including trafficking through the 
TGN, or be trafficked to lysosomes for subsequent degradation(102-104). A major 
mechanism of endosomal regulation is through the action of Rab GTPases. 
Rab GTPases are part of the family of small GTPase proteins and are major 
regulators of endosomal dynamics(71, 105, 106). These proteins cycle on and off of 
endosomes to help regulate membrane trafficking. Inactive Rab proteins are soluble 
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and located diffusely in the cytosol bound by Rab GDP-dissociation inhibitors(104, 
107). Whereas, active Rab proteins are located on specific endosomal populations 
and intracellular organelles to regulate vesicular transportation. The various Rab 
proteins allow for compartmentalization of the endocytic trafficking pathway. Rab5 is 
located on early endosomes whereas other Rabs including Rab4 and Rab11 
regulate recycling endosomes(71, 105). Rab4 regulates endosomal traffic back to 
the plasma membrane from early endosomes and Rab11 regulates recycling from a 
less well-defined perinuclear recycling compartment(108, 109). Two other well-
characterized Rab proteins include Rab7, which functions to allow for vesicular 
transport between the endocytic pathway and lysosomes, and Rab9 regulates 
trafficking of cargo between late endosomes and the Golgi complex(110, 111). 
Numerous GPCRs traffic through Rab containing endocytic compartments 
depending on protein-protein binding and post-translational motifs. For examples, 
the µ-opioid receptor (µOR) traffics through Rab4 or Rab11-positive endosomes 
depending on its phosphorylation state. Only non-phosphorylated µOR can recycle 
to the plasma membrane through Rab11-positive endosomes whereas 
phosphorylated receptor recycles primarily in Rab4-positive endosomes(112). 
Additionally, endosomal protein-protein interactions have been shown to alter the 
endocytic fate of numerous receptors including β2AR, LHR, and PTHR1(70, 86).  
While a receptor’s ability to traffic into different endosomal populations depending on 
protein-protein interactions and post-translational modifications has been well-
described, a more detailed understanding of the mechanisms of receptor sorting is 
beginning to emerge. Receptors are sorted along each step of the endocytic 
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pathway and detailed sorting occurs within microdomains on the endosome. 
Differential sorting within these microdomains is sufficient to alter both the endocytic 
fate of the receptor and alter its signaling(94, 101, 113, 114).  
Sorting at the endosomes is a dynamic and highly regulated process. 
Receptors can either be sorted into intraluminal vesicles to eventually be degraded 
in lysosomes or can be sorted into specific endosomal domains to be further 
trafficked along the endosomal pathway or to be returned to the plasma membrane. 
This occurs in a coordinated fashion and depends upon the protein machinery 
present at the endosome. 
A major mechanism of endosomal sorting is through the retromer complex of 
coat proteins, which is an evolutionarily conserved complex of endosomal proteins. 
While the complex was originally discovered in yeast, mammalian cells have a highly 
homologous complex composed of five proteins, SNX1/2, SNX5/6, Vps26, Vps29, 
and Vps35, and acts to sort cargos from the late endosome to the trans-golgi 
network during retrograde trafficking (115). The retromer complex has been shown 
to be involved in the trafficking of other GPCRs including the β2-adrenergic receptor 
(β2AR) and the parathyroid hormone receptor 1 (PTHR1) (75, 116). It also functions 
to sort a wide variety of other protein cargos such as the cation-independent 
mannose-6-phosphate receptor (CI-M6PR) and Wntless(117).  The balance 
between recycling and degradation is crucial to maintain specific plasma membrane 
receptor levels. In fact, disruption of the retromer complex is associated with a 
variety of diseases including Alzheimer’s and Parkinson’s disease and knockout of 
the retromer subunits is embryonically lethal, indicating the critical role of the 
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retromer in cellular homeostasis(118). Additionally, the retromer complex has been 
shown to be crucial for the regulation of Wnt secretion and also for the coordination 
of GPCR signaling at the endosome(119, 120). The retromer has been shown to be 
a crucial regulator of receptor trafficking and therefore a major regulator of receptor 
signaling. 
 
1.6 PDZ Domain Proteins 
PDZ proteins are named for a structural domain that is present on 
postsynaptic density protein (PSD95), Drosophila disc large tumor suppressor 
(DlgA), and zonula occludens-1 protein (ZO-1)(86, 87, 121). About 200-300 PDZ 
proteins are in the mammalian genome and are cytoplasmic adaptor proteins that 
allow for assembly of multi-protein signaling complexes(86). The PDZ domain itself 
is composed of six β-sheets and two α-helices and the ligand binds between second 
β-sheet and second α-helix and allows for a large flexibility in binding to different 
ligands with a single PDZ domain being able to bind to potentially hundreds of PDZ 
ligand containing proteins(122). This allows for intricate spatial and temporal control 
of receptor signaling. PDZ domain containing proteins can contain single or multiple 
PDZ domains along with other protein-protein binding motifs, allowing for the 
production of large protein signaling complexes. Increasingly, PDZ domain 
containing proteins have been shown to regulate numerous aspects of GPCR 
signaling and trafficking. While there are now numerous examples in the literature, 
the β2-adrenergic receptor (β2AR) was the first example of a GPCR function being 
regulated by a PDZ domain protein. β2AR was shown to bind to NHERF1 to allow 
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β2AR to regulate the NHE3 sodium-protein exchanger(123). PDZ proteins have 
been shown to switch G-protein coupling, alter β-arrestin binding, tether receptors at 
the plasma membrane, and bind to downstream signaling effectors such as protein 
kinase A (PKA) and phospholipase C (PLC) amongst other functions(86). Binding to 
PDZ domain proteins allows GPCRs to exert both receptor-specific and cell-specific 
effects. 
 
1.7 The Role of PDZ domain containing proteins in GPCR trafficking 
 Increasingly, GPCR trafficking has been shown to be regulated by numerous 
elements including binding to cytoplasmic adaptor proteins. This regulation in turn 
affects GPCR function. PDZ domain proteins can influence receptor trafficking 
through tethering the receptor at the plasma membrane, directing receptors in early 
endosomes or very early endosomes, and directing receptors into specific recycling 
pathways(70, 86).  β2AR was the first GPCR whose trafficking was shown to be 
regulated by PDZ domain proteins. The PDZ ligand allowed β2AR to be sorted into a 
recycling pathway to be returned to the plasma membrane after internalization(124). 
Consistent with the hypothesis that receptors need to recycle through specific 
pathways for resensitization, PDZ ligand dependent recycling of β2AR was also 
shown to enhance the cAMP response after prolonged stimulation of β2AR(125). A 
great deal of work has since been done on the role of the β2AR PDZ ligand in 
receptor trafficking.  
Type I PDZ ligands have since been shown to be sufficient for receptor 
recycling by fusing the last 10 amino acids to a non-recycling receptor, the δ-opioid 
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receptor (δOR)(126, 127). Normally, δOR is trafficked to lysosomes for degradation 
after internalization, however its endocytic fate can be altered and the receptor can 
be rerouted to the plasma membrane when the last 10 amino acids of β2AR are 
fused to the receptor. This recycling is dependent upon an intact PDZ ligand as 
adding the last 10 amino acids with the final C-terminal amino acid mutated to an 
alanine to disrupt PDZ binding is not sufficient to change δOR to a recycling 
receptor. Later the PDZ domain was shown to be required for β2AR to be localized 
in specific endosomal tubules, which is required for both signaling and the endocytic 
fate of the receptor. Similarly, the PDZ ligand of the β1-adernergic receptor (β1AR) 
is also required for receptor recycling(128). β1AR binds to SAP97 through a PDZ 
mediated interaction allowing the receptor to complex with AKAP79. This complex 
allows for PKA mediated phosphorylation of a 3rd loop site that is also required for 
recycling(128, 129).  
Interestingly, some GPCRs can bind to multiple PDZ domain proteins that 
have opposing effects on receptor function. For example, the serotonin 2C receptor 
(5HT2CR) can bind to both PSD95, which promotes endocytosis and 
desensitization, and MPP3, which tethers the receptor at the membrane and 
promotes resensitization(130). Other GPCRs whose intracellular trafficking is 
regulated by PDZ ligand-domain interactions include CXCR2 chemokine receptor, 
which protects it from trafficking to lysosomes and subsequent degradation, the 
luteinizing hormone receptor (LHR) whose PDZ ligand allows for trafficking into very 
early endosomes (VEEs) and promotes recycling, and the thyrotropin stimulating 
hormone receptor (TSHR) whose ligand allows for tethering at the plasma 
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membrane and promoting recycling(131-133). PDZ ligand-domain interactions have 
been shown to be crucial regulators of GPCR trafficking, regulation, and signaling. 
 
1.8 SHANK Proteins 
The SHANK family of proteins consists of three members, SHANK1, 
SHANK2, and SHANK3, which are large synaptic scaffolding proteins(134). SHANK 
proteins have been best studied in the central nervous system as they are present at 
nearly all excitatory glutaminergic synapses(135). They play critical roles in 
numerous neuronal processes including actin/cytoskeleton remodeling, AMPA 
receptor endocytosis, synapse formation, glutaminergic transmission, and synaptic 
plasticity. The role of SHANK proteins in human neuronal disease was first 
recognized when SHANK3 loss was recognized as the cause of intellectual disability 
in Phelan-McDermind Syndrome (PMS)(136). Since then, mutations, deletions, and 
duplications of the three SHANK proteins have been found in numerous patients 
with autism, schizophrenia, and bipolar disorder(137, 138). 
All three SHANK proteins have the same basic structure with N-terminal 
ankyrin repeats, an SH3 domain, a PDZ domain, a large proline rich region, and a C-
terminal sterile alpha motif (SAM)(Fig 4)(139, 140). These various protein-protein 
binding motifs allow all three SHANK proteins to bind to a large number of other 
proteins, over 30 binding partners have been identified, and they act as major 
organizers at the post-synaptic density. These binding proteins include ion channels, 
GPCRs, other scaffolding proteins, enzymes, and cytoskeletal proteins. SHANK1, 
SHANK2, and SHANK3 are highly homologous and indeed can bind to many of the 
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same proteins(135). SHANK proteins are major organizers at the post-synaptic 
density (PSD) and allow for receptors to be linked to their downstream protein 
machinery for rapid signal transduction.  
 
 
 
 
 
 
  
Figure 4: Structure of SHANK proteins. All three SHANK family members 
contain the same basic structure consisting of ankyrin repeats (ANK), a src 
homology 3 domain (SH3), a postsynaptic density protein (PSD95), Drosophila 
disc large tumor suppressor (Dlg1), zonula occludens-1 protein (ZO-1) domain 
(PDZ), a large proline rich region, and a sterile alpha motif (SAM). These 
protein-protein domains allow for SHANK proteins to act as large molecular 
scaffolds and act as regulators at the post-synaptic density and other cellular 
microdomains. 	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All three SHANK proteins show broad distribution throughout the brain but do 
show different expression patterns and subcellular localizations(141, 142). The 
degree of functional overlap between the three SHANK proteins is still unknown. All 
three SHANK proteins are extensively spliced and regulated through multiple 
intragenic promoters(139). Six intragenic promoters have been identified for 
SHANK3 and although multiple different protein isoforms have been characterized, it 
is possible that additional isoforms in various tissue types have yet to be 
identified(143). Each SHANK3 isoform contains a unique set of protein-protein 
binding domains likely allowing for each isoform to confer a specific function. It is 
thought that the wide array of isoforms contributes to signaling specificity. Some of 
the isoforms of SHANK proteins have been shown to have unique functions. 
Interestingly, the SAM domain of SHANK2 and SHANK3 is required for synaptic 
targeting, although this is not the case for SHANK1. The SAM domain also allows for 
SHANK3 to scaffold to itself and is thought to be crucial for organization of the post-
synaptic density. Additionally there is some clinical data suggesting that certain 
isoforms play specific signaling roles, as patients with mutations in SHANK3 only 
have these mutations in certain isoforms further suggesting that each isoform serves 
a specific function that cannot be compensated for by alternative isoforms(144).  
SHANK1 and SHANK2 have been shown to bind to sst2 through their PDZ 
domains(88-90). They were initially identified as sst2 binding proteins using a yeast 
2 hybrid screen with the C-terminal of sst2 as bait and a human brain cDNA library. 
Although the group that identified these binding partners were not able to find a 
function for this protein-protein binding, they concluded that SHANK2 is recruited to 
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the plasma membrane in sst2 expressing cells after stimulation with SS14. Although, 
a change in subcellular localization of SHANK2 was identified after stimulation with 
SS14, no specific function altering sst2 signaling or regulation was identified. It is 
likely that SHANK1, SHANK2, and SHANK3 have different effects on sst2 regulation 
and signaling, allowing sst2 to exert context specific effects when activated. 
Interestingly, SHANK2 and SHANK3 were also identified in rat pituitary cells, 
specifically somatotrophs, indicating that SHANK proteins likely play a role in sst2 
regulation in the pituitary(145). An important outstanding question is which isoforms 
of SHANK2 and SHANK3 are present in the pituitary, as this would determine both 
the possibility for these proteins to interact with sst2 in a PDZ dependent manner, 
and would affect the specific regulatory effects they had on sst2. Of note, we 
determined that SHANK expression varies between rat and human and while 
SHANK2 and SHANK3 are expressed in rat pituitary, SHANK1 and SHANK3 are 
present in human pituitary tissue.  
 
1.9 Summary 
 Sst2 plays a crucial role in both the physiologic control of hormone secretion 
as well as the treatment of pathologic hormone secretion from neuroendocrine 
tumors. In addition to these roles, sst2 activation has well-established effects on cell 
growth and proliferation, cell migration, and neuromodulation. How sst2 exerts these 
cell type and context specific effects is an important outstanding question. 
Additionally, the mechanisms governing neuroendocrine tumor resistance to 
somatostatin analogs have yet to be elucidated. Resistance to somatostatin analogs 
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is a significant clinical challenge as there are limited additional options to control the 
pathological hormone secretion associated with functional NETs. The different 
patterns of resistance in pituitary versus GI and pancreatic NETs points to multiple 
mechanisms of resistance to somatostatin analogs despite the continued presence 
of sst2 on the cell surface of these tumors. 
Sst2 has a highly conserved PDZ ligand at its C-terminal tail and what role 
this motif plays in sst2 signaling, trafficking, and regulation was unknown before this 
study. We hypothesize that uncoupling from sst2’s downstream signaling machinery 
is a major mechanism of NET resistance to somatostatin analogs. While many of the 
major pathways through which sst2 exerts its effects have been well described, 
much is left to learn about sst2’s trafficking, regulation, and cell specific effects. As 
PDZ ligand-domain interactions allow for specific spatial and temporal signaling and 
regulation of receptors, we asked what effect PDZ protein binding played for sst2 
signaling, trafficking, and regulation. We determined that the PDZ ligand plays a 
significant role in sst2 intracellular trafficking by showing that the sst2 PDZ ligand 
was sufficient for receptor recycling and that sst2 mutants lacking the PDZ ligand or 
C-terminal amino acids are routed through different intracellular pathways in 
comparison to wild type receptor. We have yet to associate this with an alteration in 
signaling. How intracellular trafficking influences receptor signaling is an important 
general question to understand how receptors create highly specific signals. We also 
determined that sst2 regulation and cell surface expression is influenced by PDZ 
domain containing proteins, SHANK3 co-expression increases sst2 plasma 
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membrane expression. It is still unclear as to what the mechanism behind this 
finding is.  
Understanding how SAs exert their effects on NETs is crucial in order to 
overcome resistance to SAs and to improve treatments for both hormone secretion 
and tumor growth. We have demonstrated that NETs can lose sst2 PDZ binding 
partners altering their intracellular trafficking and possibly alters the response to 
SAs. The newest clinically used SA, pasireotide, does not cause receptor 
internalization, likely altering the signaling profile of sst2 once stimulated in 
comparison to SAs such as octreotide. Understanding how PDZ proteins interact 
with and affect sst2 will help us better understand how sst2 exerts its effects in a cell 
type specific manner and the effects of SA on NET growth and hormone secretion.  
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Chapter 2 
Methods 
 
2.1 Reagents 
Anti-FLAG epitope rabbit polyclonal (600-401-383; 1:5000 for western blot 
and 1:2000 for immunocytochemistry) and anti-HA epitope rabbit polyclonal (600-
401-384; 1:2000 for immunocytochemistry) were purchased from Rockland 
Immunochemicals. Anti-HA epitope mouse monoclonal (MMS-101R; 1:10,000 for 
western blot, 1:2000 for immunocytochemistry) was purchased from Biolegend. Anti-
M6PR (cation independent) mouse monoclonal (ab2733; 1:500 for 
immunocytochemistry) antibody was purchased from Abcam. Rabbit anti-EEA1 was 
purchased from Thermo Fisher (1:2000 for western blot) and mouse anti-LAMP was 
purchased from Developmental Studies Hybridoma Bank (H4A3; 1:2000 for western 
blot). Mouse anti-SHANK1 (N22/21, Tissue supernatant; 1:2 for western blot), 
mouse anti-SHANK2 (N23B/6; 1:1000 for western blot), and mouse anti-SHANK3 
(N367/62: 1:1000 for western blot) were purchased from Neuromab (Davis, CA).  
Rabbit anti-SHANK3 (H-160; 1:5000 for western blot) and mouse anti-GAPDH 
(1:500 for western blot) were purchased from Santa Cruz. Rabbit anti-total ERK1/2 
(4695; 1:5000 for western blot) and rabbit anti-p42/44 ERK1/2 (8544; 1:1000 for 
western blot) were purchased from Cell Signaling (Danvers, MA).  Rabbit anti-GFP 
(1:5000 for western blot) was purchased from Thermo Fisher. AlexaFluor fluorescent 
secondary antibodies were purchased from Invitrogen. Tat peptides, TAT-AAA: 
GRKKRRQRRRPPQGGGLLNGDLQAAA and TAT-SST2: 
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GRKKRRQRRRPPQGGGLLNGDLQTSI, to block PDZ interactions were 
synthesized by Lifetein (Somerset, NJ). Somatostatin 14 (SS14) and PRL2915 were 
purchased from Bachem. [D-Ala2, D-Leu5] Enkephalin (DADLE) and [D-Ala2, NMe-
Phe4, Gly-ol5]-enkephalin (DAMGO) were purchased from Tocris. Naloxone was 
purchased from MP Biomedicals. Jetprime transfection reagent was purchased from 
Polyplus Transfection (Illkirch, France). Genetecin (G418) was purchased from 
Cellgro (Oneonta, NY). Fluo8-AM was purchased from TEFLabs (Austin, TX). FLIPR 
membrane potential assay blue component dye was purchased from Molecular 
Devices (Sunnyvale, CA).  
 
2.2 Cell Culture, Stable Cell Lines, and Transfections 
All cells were grown at 37°C in a humidified 5% C02 incubator. Human 
embryonic kidney 293 cells (HEK293) were grown in Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Lonza) with 10% fetal bovine serum (FBS)(Atlanta Biologicals). 
GH12C1 cells were grown in DMEM with 10% FBS. GH4C1 cells were grown in 
Ham’s F12 (F12) media (Lonza) with 12.5% horse serum (HS) (Atlanta Biologicals) 
and 2.5% FBS. AtT20 cells were grown in DMEM with 10% FBS. IMR32 cells were 
grown in RPMI 1640 media supplemented with 10%FBS and 1% L-glutamine. 
CNDT2.5 cells were grown in DMEM/F12 with 10% FBS, 1mM sodium pyruvate, 
MEM non-essential amino acids, MEM vitamin solution, and 2mM L-glutamine. BON 
cells were cultured in DMEM/F12 +10%FBS. Clonal cell lines stably expressing 
receptor plasmid were isolated by limited dilution and cultured in the media of the 
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parental cell line supplemented with 250µg/mL Geneticin (G418). Transient 
transfections were performed the day before experiments using Jetprime.  
 
2.3 cDNA Constructs 
The triple HA-epitope tagged rat sst2 wild type plasmid has been described 
previously(82). Triple HA-epitope tagged sst2 ΔTSI (lacking the 3 C-terminal amino 
acids, TSI) and sst2 358T (ending at amino acid 358) were made by PCR 
amplification using Kapa Hifi polymerase (Kapa Biosystems, Wilmington, MA). Sst2 
was amplified from an internal BamHI site to the 3’ end using a mutagenic primer 
with a stop codon before the last 3 or 10 amino acids. The PCR product was 
digested with BamHI (New England Biolabs) and HindIII (New England Biolabs) and 
ligated into sst2. Triple HA-epitope tagged and FLAG-epitope tagged mouse delta 
opioid receptor (δOR) constructs were made by amplifying δOR from a cDNA 
construct donated by Michael Zhu and digested into pcDNA3.1 with either an N-
terminal triple HA tag or a N-terminal FLAG tag with a signal sequence using EcoRI 
(New England Biolabs)  and XhoI (New England Biolabs). A KpnI cut site at amino 
acid 367 of δOR was introduced by PCR into 3xHA-δOR to create the chimeric 
receptors. Complementary oligonucleotides spanning the last 30 base pairs of sst2 
or spanning the region encoding 7 of the last 10 amino acids of sst2 (lacking the 3 
C-terminal amino acids) were purchased (Sigma) and annealed by one cycle of 
heating and slow cooling. Both double stranded inserts contained a 5’ KpnI 
overhang and a 3’ XhoI overhang to enable ligation into the δOR construct at the 
KpnI (New England Biolabs) site. GFP-Rab4 S22N and GFP-Rab11 S25N were 
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produced using site directed mutagenesis from GFP-Rab4 and GFP-Rab11 
plasmids (Kapa Hifi, Kapa Biosystems, Wilmington, MA). FLAG tagged SHANK PDZ 
domain plasmids were made by amplifying the PDZ domains of the three SHANK 
proteins from HA-SHANK1 and HA-SHANK3 donated by Carlo Sala and SHANK2 
cDNA purchased from the Harvard Plasmid Repository. NotI and BamHI sites were 
added by PCR and products were digested and ligated into pFLAG-CMV-6b. GFP-
SHANK1 (terminates at amino acid 1509 and lacks the SAM domain due to poor 
expression of full length clone) was made by amplifying SHANK1 from HA-SHANK1 
to add a 5’ HindIII and 3’ SalI site, was ligated into eGFP-C1 (Clontech). GFP-
SHANK3 was made by PCR from HA-SHANK3, a 5’ EcoRI and 3’ SalI site were 
added, and the PCR product was ligated into eGFP-C3. GFP-SHANK2 was made by 
PCR from SHANK2 cDNA, a 5’ SalI and 3’ KpnI cut site were added, and the 
product was ligated into eGFP-C1. The SHANK3 truncation plasmid GFP-SHANK3 
1334T was made by digesting GFP-SHANK3 with EcoRI and KpnI (an internal cut 
site) and ligating the truncated product into GFP-C3. GFP-SHANK3 1448T was 
made by amplifying SHANK3 from amino acid 1334 to 1448 by PCR and ligating the 
product into GFP-SHANK3 1334T using KpnI and XhoI. All plasmids were verified by 
sequencing. 
 
2.4 Receptor ELISAs 
Cell surface receptors were measured using a colorimetric peroxidase assay 
as described previously(80). HEK293 cells were plated in poly-l-ornithine (Sigma 
Aldrich) coated 96 well plates 1 day prior to transfection and used for experiments 1 
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day after transfection. The day of the experiment, cells were washed with DMEM 
with 5 mg/mL Lactalbumin Hydrolysate (LH) and 20 mM HEPES (pH 7.4) and 
incubated with primary antibody (mouse anti-HA, 1:10,000, Biolegend) for 2 h at 
4°C. After washing twice with DMEM/LH/HEPES and incubating (37°C for 20 min.), 
agonist was added (100 nM SS14 or 1 µM DADLE) for the indicate time periods. 
Cells were subsequently washed with cold phosphate buffered saline (PBS) and 
fixed in 3% paraformaldehyde (PFA) in PBS. To visualize the recycled receptor, cells 
were incubated with goat anti-mouse horse radish peroxidase (HRP) in 1% bovine 
serum albumin (BSA) in PBS for 1 h at room temperature (RT) and then incubated 
with the colorimetric peroxidase substrate, 2,2’-azino-bis(3- ethylbenzthiazoline-6-
sulfonic acid (ABTS) for 45 min. Absorbance was read at 405 nm. The absorbance 
of untransfected wells was subtracted as background and absorbance was 
compared to untreated wells on the same plate. To determine total receptor levels, 
cells were fixed in 3% PFA, permeabilized with 0.3% Triton X-100 in 1% BSA in PBS 
for 20 min at RT, then incubated with anti-HA antibody diluted in the 
permeabilization buffer for 1 h at RT, and the rest of the assay was completed in the 
same manner as the cell surface ELISA.  
To measure sst2 recycling, after cells were incubated with primary antibody 
(as described for cell surface experiments), they were then washed twice and 
incubated in DMEM/LH/HEPES supplemented with 15 mM NaHCO3 (37 °C in a 5% 
CO2 incubator for 20 min). Appropriate agonist, SS14 or DADLE (see figure 
legends), was added for 30 min to reach a steady state of internalization (80). Cells 
were washed twice with assay media and then incubated with fresh media 
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containing either 100 nM PRL2915, an sst2 specific antagonist, or 1 µM Naloxone, 
an opioid receptor antagonist, to inhibit the action of residual agonist that remained 
in the reaction. The cells were incubated (37°C in 5% CO2) for the time points 
indicated and subsequently fixed. They were then incubated with secondary 
antibody, followed by color development with ABTS. Recycling assays with GFP-
Rab4 S22N or GFP-Rab11 S25N were performed using the same approach 
following transfection with receptor and a vector containing GFP-Rab4 S22N, GFP-
Rab11 S25N, or GFP. Recycling end points were plotted as the extent of recycling 
using the formula (%recycled - %internalized)/100 - %internalized.  
 
2.5 Whole Cell cAMP Measurements 
Whole cell cAMP was measured using the Glosensor cAMP assay according 
to the manufacturer instructions (Promega, Madison, WI). Briefly, HEK293 cells were 
transiently transfected with both receptor and Glosensor 22F plasmids. Empty 
pcDNA3.1 vector was transfected as a control. The following day, cells were 
preincubated in DMEM with 10% FBS and 2% D-luciferin for 2 h at 28°C. Baseline 
luminescence readings were taken before the addition of agonist. Cells were 
stimulated with either 10 µM NKH477 alone or 10 µM NKH477 plus varying 
concentrations of SS14. Luminescence was normalized to NKH477 alone.  
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2.6 Immunofluorescence Staining and Confocal Imaging 
HEK293 cells were seeded on poly-l-lysine (Sigma Aldrich) coated glass 
coverslips. For co-localization with Rab4 or Rab11, cells were transiently transfected 
with receptor and either GFP-Rab4 or GFP-Rab11 the day before the experiment. 
Cells were incubated at 4°C with anti-HA antibody for 2 h to label receptors. Cells 
were subsequently washed in DMEM/LH/HEPES, warmed to 37°C and treated with 
100 nM SS14 for 30 min, washed, and incubated with 100 nM PRL2915 for 15 min 
to allow for receptor recycling, and then fixed in 3% PFA in PBS. For dual staining of 
3xHA-sst2 and FLAG-δOR, cells were preincubated with both mouse anti-HA and 
rabbit anti-FLAG antibodies for 2 h at 4°C, washed, warmed in fresh media to 37°C, 
treated with both 100 nM SS14 and 1 µM DADLE, and fixed in 3% PFA in PBS. 
Cells were blocked and permeabilized using 0.3% Triton X-100 in 10% goat serum 
in PBS for 30 min, and incubated with Alexa Fluor conjugated secondary antibodies, 
anti-mouse Alexa 568 and anti-rabbit Alexa 488 (Invitrogen), diluted in 10% goat 
serum in PBS for 1 h at RT. Cells were washed, co-stained with 1 µg/mL 4’,6-
diamidino-2-phenylindole (DAPI), and mounted on glass slides using Prolong Gold 
Antifade Mountant (ThermoFisher). M6PR staining was performed in a similar 
manner except that cells were fixed and permeabilized in cold methanol after 
treatment, followed by a 1h incubation with anti-M6PR antibody diluted in 3% BSA in 
PBS. Cells were imaged using a Leica SP8 confocal microscope at 63x 
magnification and analyzed using ImageJ. Pearson’s correlation coefficients were 
generated using ImageJ by comparing images from green and red channels. 
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2.7 Immunoprecipitation, Biotinylated Peptide Pulldown, and Western Blots 
HEK293 cells were transfected with HA tagged receptors and treated for 15 
min with 100 nM SS14 at 37°C for 15 min. Cells were then placed on ice, washed 
with cold PBS, and scraped into anti-phosphatase buffer (150 mM NaCl, 20 mM 
HEPES, 5 mM EDTA, 3 mM EGTA, 10 mM Na Pyrophosphate, and 10 mM NaF at 
pH 7.4). Cell pellets were solubilized using anti-phosphatase buffer with 2 mg/mL 
dodecyl β-maltoside, 10 ng/mL leupeptin, 20 ng/mL soybean trypsin inhibitor, 50 
ng/mL bacitracin, 1 mM phenylmethylsulfonyl fluoride, and 1 µM okadaic acid for 2 h 
at 4°C, and centrifuged (16,000 x g, 20 min). 0.5 ng/mL anti-HA antibody was added 
for 1 h followed by 1 h with Protein-G Sepharose. Pellets were washed 3 times with 
lysis buffer, eluted in urea sample buffer (125 mM Tris-HCl pH 6.8, 4% SDS, 20% 
glycerol, 6M urea), and resolved by 10% SDS-PAGE. After transfer to polyvinylidene 
difluoride (PVDF) membrane, immunoprecipitates were tested by western blotting 
with previously described sst2 phospho-antibodies(79). 
For the biotinylated peptide pulldowns with SHANK PDZ domains, FLAG 
tagged SHANK PDZ domains were transiently transfected into HEK293 cells using 
Jetprime transfection reagent (Polyplus). Cells were harvested, pelleted, and lysed 
in anti-phosphatase buffer with 0.5% Nonidet P40, 10ng/mL leupeptin, 20ng/mL 
soybean trypsin inhibitor, 50ng/mL bacitracin, 1mM phenylmethylsulfonyl fluoride, 
and 1µM okadaic acid and spun to remove any insoluble material. 4nM of 
biotinylated peptides (sst2 or sst2-AAA) were incubated with 50uL streptavidin 
agarose beads (Pierce) for 1 hr at 4°C and then washed 3 times with PBS to remove 
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any unbound peptide. The remaining free avidin sites were blocked with 10ug of 
biotin for 10 min at room temperature. The pellet was then washed again with PBS 
to remove unbound biotin. Lysates were pre-cleared with 50uL control agarose 
beads for 1 hr at 4°C and centrifuged to remove the agarose. The pre-cleared 
lysates were then added to the peptide-streptavidin beads and incubated at 4°C for 
2 hrs. Beads were then washed 4 times with 1mL wash buffer (50mM HEPES 
pH7.4, 200mM NaCl, 0.5% Triton X100, 0.2% deoxycholate, 1mM PMSF, 10ng/mL 
leupeptin, 20ng/mL soybean trypsin inhibitor, and 50ng/mL bacitracin) followed by 1 
wash with 100mM Tris pH 8 to remove excess detergents and salt. Bound proteins 
were then eluted in SDS buffer for 10 min at 60°C. Eluates were then analyzed by 
western blot. 
To determine ERK phosphorylation, HEK293 cells stably expressing sst2 
were incubated in DMEM/LH/HEPES at 37°C for 20min with 100nM TAT-sst2 or 
TAT-AAA peptides. Cells were then treated with 100nM SS14 for the times 
indicated, placed on ice, and scraped into HEPES buffer (150mM NaCl, 20mM 
HEPES, 5mM EDTA, 3mM EGTA) with 1% Triton X-100. Cells were incubated for 
20min on ice and then spun at X g for 20min. Samples were diluted in 2x Laemmli 
buffer (1M Tris, 20% glycerol, 10% SDS) and run on 12% SDS-PAGE gel, 
transferred to PVDF membranes, blocked with 5% BSA and probed for phospho-
ERK and then total ERK. 
For SHANK immunoblotting, brain cortex and pituitary were dissected from 
sacrificed male Sprague Daley rats and mouse cortex was dissected from male 
C57/B6 mice and snap frozen with liquid nitrogen. Tissues were then ground, 
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homogenized in RIPA buffer (10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 1% Triton X-100, 
0.1% sodium deoxycholate, 0.1% SDS,140 mM NaCl, 1 mM PMSF), left on ice for 
15 min and spun to remove insoluble material. Samples were diluted in 2x Laemmli 
buffer (1M Tris, 20% glycerol, 10% SDS) and run on 8% SDS-PAGE gel, transferred 
to PVDF membranes, blocked with 5% milk and probed using various SHANK 
antibodies. Cell lysates were also made using RIPA buffer and mechanically lysed 
using a 25 gauge needle. 
 
2.8 Gradient Endosome Separation 
HEK293 cells were plated in 10 cm dishes 2 days before the experiment and 
transfected with 3xHA-sst2 using Jetprime the day before the experiment. Cells were 
washed twice and incubated at 37°C for 20 min prior to the addition of agonist. 100 
nM SS14 was added for the indicated times. Cells were washed with cold PBS, 
scraped into cold PBS, and pelleted by centrifugation (3000 x g, 10 min). Post-
nuclear supernatants were isolated and loaded on top of a continuous Opti-prep 
gradient (Sigma, 10-20%) and centrifuged (150,000 x g, 12 h, 4°C) in a swinging 
bucket rotor (TLS-55, Beckman). Fractions (150 µL) were collected and diluted in 
homogenization (HB) buffer (20 mM HEPES pH 7.4, 0.25 M sucrose, 2 mM EGTA, 2 
mM EDTA, 0.1 mM DTT and a protease inhibitor cocktail (112 µM PMSF, 3 µM 
aprotinin, 112 µM leupeptin, 17 µM pepstatin) (150 µL) followed by centrifugation 
(150,000 x g, 1 h, 4°C). The resulting pellet was resuspended in urea sample buffer 
for western blotting or diluted in HB for use in the endosomal budding assays (see 
below). 
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2.9 Cytosol Preparation 
The Saccharomyces cerevisiae strains, wild type (MATa; his3Δ 1; leu2Δ 0; 
met15Δ 0; ura3Δ 0) and ΔSNX1/2 (MATa; his3Δ 1; leu2Δ 0; ura3Δ 0; met15Δ 0; 
snx1::KANMX6) were plated on yeast extract peptone dextrose (YPD plates) (500 
mL ddH20 containing: 10 g bactopeptone, 5 g yeast extract, 8 g agar, 25 mL 40% 
dextrose) and incubated for 48 h in a shaker at 30°C. YPD media (5 mL) was 
inoculated with various Saccharomyces cerevisiae strains and incubated overnight 
in a shaker at 30°C. Cultures were transferred into a secondary culture of YPD 
media (50 mL) and were grown until OD600 reached 0.8-1.0. For Saccharomyces 
cerevisiae ΔSNX1/2, the strain was grown in YPD media containing G418 (500 
µg/mL).  Cells were collected by centrifugation (3000 x g, 3 min) and washed twice, 
first with 500 µL of ddH2O followed by 500 µL Tris protease TP buffer (20 mM Tris, 
pH 7.9; 0.5 mM EDTA; 10% glycerol; 50 mM NaCl, 112 µM leupeptin, 3 µM 
aproptinin, 112 µM PMSF, and 17 µM pepstatin). Cells were collected by 
centrifugation (3000 x g, 3 min), resuspended in TP buffer (130 µL), and lysed using 
acid-washed glass beads (1 min vortex; 1 min incubation on ice, 5x) prior to 
centrifugation (3000 x g, 10 min) for supernatant collection. Protein concentration in 
the supernatants was measured by Bradford assay. Supernatants were divided into 
70 µg aliquots and stored at -80 °C.  
 
2.10 Endosomal Budding Assays 
For endosomal budding assays, cells were lysed and endosomes were 
separated on Opti-prep gradients. Gradient fractions containing late endosomes 
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were pooled and incorporated into the cell-free budding assay. Late endosome 
fractions were diluted in HB (400 µL) and centrifuged (150,000 x g, 1 h, 4°C). The 
resulting pellets were resuspended in 15 µL HB and membranes were used in cell-
free reactions as described(146). Endosomal membranes were either incubated on 
ice (starting material) or incorporated into reactions containing yeast cytosol. A 
standard reaction (50 µL) contained 15 µL endosomal membranes, 6 µL ATP 
regeneration system (2 mM Mg-ATP, 50 µg/mL creatine kinase, 8 mM 
phosphocreatine, 1 mM DTT), 70 µg of Saccharomyces cerevisiae cytosol, and HB 
in a total reaction volume of 50 µL. Experimental reactions were incubated for 3 h at 
37°C, followed by trypsin-treatment (6 µl of 0.27 µg/µL trypsin; 30 min, 4°C). 
Reactions were centrifuged (20,000 x g, 30 min, 4°C), supernatants were collected 
and further centrifuged (150,000 x g, 1 h, 4°C) to obtain outwardly budded vesicles. 
After ultracentrifugation, the resulting pellet was resuspended in Laemmli sample 
buffer for SDS-PAGE. Control reactions (starting material) remained on ice 
throughout the entirety of the experiment and were resuspended in Laemmli sample 
buffer for SDS-PAGE. Proteins were then transferred to PVDF membrane and 
assessed by western blotting using the denoted antibodies and visualized using 
enhanced chemiluminescence. The resulting band densities were quantified using 
ImageJ. 
 
2.11 Membrane Hyperpolarization Assays 
GH12C1 cells were plated in black walled 96 well plates 1 day prior to the 
experiment. Cells were washed once with assay buffer (140mM NaCl, 2mM CaCl, 
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1mM MgCl, 5mM KCl, 10mM Glucose and 10mM HEPES, pH 7.4) and cells were 
then incubated with FLIPR Membrane Potential Assay Blue Component dye 
(Molecular Devices) in assay buffer and 100nM TAT-AAA or TAT-sst2 and incubated 
at 37°C for 30 min in the Flexstation 3 (Molecular Devices). Cells were excited at 
530nM and measured fluorescence was read at 565nM for 30 sec before the 
addition of 100nM SS14 diluted in assay buffer and for 5 min after the addition of 
agonist. Fluorescence was normalized to readings before the addition of agonist.  
 
2.12 Intracellular Calcium Measurements 
GH12C1 cells were plated in black walled 96 well plates 1 day prior to the 
experiment. The day of the experiment, cells were washed with ECSP buffer 
(140mM NaCl, 2mM CaCl, 1mM MgCl, 5mM KCl, 10mM Glucose and 10mM 
HEPES, pH 7.4), and 50µl of ECSP buffer with 1mM Fluo-8 AM (TEFLabs), 0.01% 
bovine serum albumin (BSA), and 2mM probenecid were added to each well and 
cells were incubated at 37°C for 45 min with 100nM TAT-AAA or TAT-SST2. Cells 
were then washed and fresh ECSP buffer was added. Cells were then incubated at 
37°C in the Flexstation 3 (Molecular Devices) for 15 min. Cells were excited at 494 
nM and measured fluorescence was read at 535 nM for 30 sec before the addition of 
100nM SS14 diluted in assay buffer and for 5 min after the addition of agonist. 
Fluorescence was normalized to readings before the addition of agonist.  
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2.13 Polymerase Chain Reaction 
Brain cortex and pituitary were dissected from sacrificed male Sprague Daley rats 
and mouse cortex was dissected from male C57/B6 mice and snap frozen with liquid 
nitrogen. RNA was made using the GeneJET RNA purification kit  (ThermoFisher) 
according to protocol and subsequently treated with DNase (New England Biolabs). 
cDNA was made using the Transcriptor First Strand cDNA Synthesis Kit (Roche) 
along with appropriate no reverse transcriptase controls. PCR products were 
amplified using GoTaq (Promega). Conditions were as follows: 35 cycles of 95°C for 
30s, 58°C for 30s, 68°C for 20s. Products were resolved on a 2% agarose gel 
stained with SybrSafe (Invitrogen). Primers were purchased from Sigma Aldrich and 
are listed below. Human pituitary and pituitary tumors cDNA samples were analyzed 
by RT-PCR at Massachusetts General Hospital using the conditions above.  
Name Sequence 
rSHANK1 Fwd GTGAGGGGTTCGGGTTCGTG 
rSHANK1 Rev TCATGTTGACCACCTGGCGG 
rSHANK2 Fwd CGGCATTACACAGTGGGCTCCT 
rSHANK2 Rev TTCTATGGCCACGTTCTCTGCAGTC 
rSHANK3 Fwd CTGTGGGTTCCTATGACAGC 
rSHANK3 Rev CGAGCACTATCCTCCTCTGG 
rEef Fwd ATTGTGGGGTTGGTCGGGGT 
rEef Rev CACCTCCTCGGTGGATGGCA 
rsst2 Fwd AAGATGTCACGATAGACCCTTG 
rsst2 Rev CACGGACGAGACATTGAAGATA 
rsst5 Fwd GTCCTGCACAGAGACACG 
rsst5 Rev GCATTCAAATCCTGCTGGTC 
mSHANK1 Fwd AAGTGCTCAGCATCGGGGAA 
mSHANK1 Rev TCTTCTTCCAGGGGGAGACCA  
mSHANK2 Fwd CGGCATTACACGGTGGGCTCCT 
mSHANK2 Rev AGGGTCTAGATTCCTGGTCACCGT 
mSHANK3 Fwd CTGTGGGTTCCTATGACAGC 
mSHANK3 Rev CGAGCACCATCCTCCTCGGG 
msst2 Fwd GCTGGCTCCCCTTCTACATC  
msst2 Rev TGTCCTGCTTACTGTCGCTC  
msst5 Fwd GGACTGGGTGGAAACACACT 
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msst5 Rev GAGACAGCATTCTGCGTTGC  
mEef Fwd ATTGTGGGGCTGGTCGGAGT 
mEef Rev CACCTCCCCGGTGAATGGCA 
hSHANK1 Fwd GTGAGGGGTTTGGGTTCGTG 
hSHANK1 Rev TCATGTTCACCACCTGTCGG 
hSHANK2 Fwd AGGCACTACACCGTGGGCTCCT  
hSHANK2 Rev TTCCACAGCCATGTTCTCAGCAGCG  
hSHANK3 Fwd TGATGACAAAGTGGCTGTCCT 
hSHANK3 Rev CACAACCTTCATGACGAGGC 
hsst2 Fwd TGAGCTCTTCATGCTGGGTC  
hsst2 Rev TAGAGGAGCCCACTCGGATT 
hEef Fwd GACAGCGAGGACAAGGACAA 
hEef Rev CGATGATGTGCTCTCCCGAC  
	  
2.14 Data Analysis 
Data analysis was performed using Prism 7 (Graphpad). Analysis of variance 
(ANOVA) or other appropriate statistics were performed as indicated based on the 
assay and a p value of <0.05 was considered significant. 
 
 
 
 	    
Table 1: List of primers.  Primers were designed to specifically amplify the PDZ 
domains of the three SHANK proteins. All primers were designed using Primer3. 
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Chapter 3 
Regulation of Somatostatin Receptor 2 trafficking and signaling by C-terminal 
motifs and the retromer 
 
3.1 Introduction 
G protein coupled receptors (GPCRs) constitute the largest family of 
membrane receptors, which activate a variety of signaling pathways in response to 
extracellular stimuli.  The majority of GPCRs are internalized after ligand binding, 
following which they are either recycled back to the plasma membrane or sorted into 
degradation pathways from which they will be degraded in lysosomes or by the 
proteasome (71, 92, 95, 147, 148). The intracellular fate of GPCRs is often regulated 
by C-terminal structural elements including postsynaptic density protein (PSD95), 
Drosophila disc large tumor suppressor (Dlg1), zonula occludens-1 protein (ZO-1) 
(PDZ) ligands and other protein-protein binding motifs (70, 86, 87, 93, 149). These 
motifs are sufficient to route receptors into specific recycling or degradation 
pathways through interactions with cytoplasmic and endosomal sorting proteins (94, 
124, 126, 128). Additionally, PDZ proteins play significant roles in modulating 
receptor signaling either through directly coupling receptors with downstream 
signaling pathways or through altering receptor trafficking. Understanding how 
receptors are sorted following internalization is crucial to understanding how a 
receptor creates a highly specific signal while acting on common pathways.  
 The Gi-coupled GPCR, somatostatin receptor 2 (sst2), is a clinically important 
GPCR as it is the drug target of somatostatin analogs such as octreotide, lanreotide, 
and pasireotide. Treatment with these agonists is the main medical approach for 
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controlling excessive hormone secretion from neuroendocrine tumors (1, 2, 12, 16). 
Activation of sst2 decreases hormone secretion by inhibiting cAMP production and 
decreasing intracellular calcium concentrations (51, 54, 55). In addition, treatment 
with somatostatin analogs has been shown to decrease tumor growth (2, 16). 
Although some of the signaling and regulatory pathways of sst2 have been studied 
in great detail, little is known about its fate after internalization, or of the structural 
motifs in its cytoplasmic domain, which determine its intracellular trafficking pathway 
(7, 48, 66, 79-83). Sst2 has a highly evolutionarily conserved C-terminal class I PDZ 
ligand in its C-terminal tail, which has been shown to bind to several proteins, 
including SHANK1, SHANK2, and PDZK1 (88-91). Although PDZ ligands often 
regulate GPCR intracellular trafficking, recycling, and signaling, no function has 
been ascribed to PDZ protein binding by sst2 (70, 86, 126).  
 In addition to interaction with PDZ domain proteins, GPCR intracellular 
trafficking is often regulated by Rab proteins, which cycle on and off endocytic 
membranes and play regulatory roles in recycling events from various endocytic 
pathways (71, 106, 150-152). For example, Rab4 can regulate endosomal trafficking 
to the plasma membrane from early endosomes, and Rab11 regulates vesicle 
movement to the plasma membrane from a perinuclear recycling compartment (106, 
109). Movement of GPCRs through these different populations of Rab containing 
endosomes depends on their ability to interact with cytoplasmic proteins and their 
post-translational modifications. For example, endocytic recycling of the β2-
adrenergic receptor (β2AR) is dependent on protein-protein binding through its PDZ 
ligand. Similarly, recycling of the µ-opioid receptor (µOR) is dependent on its 
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phosphorylation, which determines its itinerary to the plasma membrane through 
Rab4 or Rab11 positive endosomes (112, 124).  
Aside from direct recycling from Rab 4 or Rab 11 positive compartments, an 
additional pathway for plasma membrane recycling routes proteins through the 
trans-Golgi Network (TGN) prior to plasma membrane targeting (153). Sst2 has, in 
fact, been shown to transit to the TGN in HEK293 cells and primary neurons (82, 85, 
154). The retromer complex of coat proteins, which is composed of five polypeptides 
(SNX1/2, SNX5/6, Vps26, Vps29, and Vps35), acts to sort cargo from the late 
endosome to the TGN during retrograde trafficking (115). Given that the retromer 
complex is involved in the trafficking of some GPCRs, including the β2AR and the 
parathyroid hormone receptor 1 (PTHR1) (75, 116), and that sst2 is partially 
localized in the TGN in both HEK293 cells and neurons, we hypothesized that the 
retromer complex plays a role in sorting sst2 at endosomes (85, 154). 
In addition to the role in trafficking, PDZ proteins play a significant role in 
GPCR signaling. Binding to PDZ proteins allows GPCRs to alter G-protein signaling, 
couple to ion channels, and allow receptors to affect downstream signaling pathways 
such as the ERK/MAPK pathways amongst others(87). PTHR1 can bind to NHERF2 
through its PDZ domain, which alters PTHR1 signaling from primarily being through 
adenylyl cyclase to PLC(155). mGLUR5 can couple to potassium channels through 
PDZ protein binding, Ret9 requires its PDZ ligand to effectively activate the 
ERK/MAPK pathway, and there are numerous addition examples of PDZ protein 
interactions allowing receptors and GPCRs to regulate these pathways(156, 157).  
	   44	  
As the main clinical role of sst2 is to decrease hormone secretion from 
neuroendocrine tumors, we asked if the PDZ ligand of sst2 played a role in the 
pathways known to affect hormone secretion. Sst2 primarily couples to Gi/Go 
proteins to inhibit adenylate cyclase (AC)(8, 10, 51). The inhibition of AC and 
subsequent reduction of cAMP levels is the main mechanism through which sst2 can 
inhibit hormone secretion(52). Additionally, there are other cAMP-independent 
mechanisms through which sst2 can inhibit hormone secretion. The activation of 
Gi/Go proteins by sst2 in GH4C1 and GH12C1 cells can activate potassium channels 
(such as G-protein gated inward rectifier) leading to membrane hyperpolarization. 
The subsequent inhibition of voltage dependent calcium channels due to membrane 
hyperpolarization causes a decrease in intracellular calcium(51, 54, 55). Reduction 
of either cAMP or intracellular Ca2+ will lead to a decrease in hormone secretion, 
and together the effect is synergistic (Fig 2) (55). The effect on K+ channels is 
pertussis toxin (PTX) sensitive, indicating the necessity of Gi/Go proteins, and 
independent of the cAMP levels, as activation of sst2 is able to hyperpolarize the cell 
membrane even in the presence of a stable cAMP analog(54, 55). Sst2 has also 
been shown to regulate calcium channels directly, through direct inhibition also in a 
PTX-dependent manner(55). We asked if any of these mechanisms were dependent 
on the sst2 PDZ ligand. Additionally, we determined if the PDZ ligand affected sst2’s 
ability to signal to the ERK/MAPK pathway. 
We have found that the PDZ ligand plays a significant role in sst2 trafficking. 
The last 10 amino acids including the PDZ ligand are sufficient for receptor recycling 
and the presence of the PDZ ligand and last 10 amino acids allows for sst2 to 
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access different recycling pathways. We also determined that trafficking of sst2 from 
the late endosome to the TGN is dependent on the presence of SNX1/2, a 
component of the retromer. Overall, the last 10 amino acids and the PDZ ligand play 
an important role in sst2 endosomal sorting and trafficking. 
 
3.2 Results  
3.2.1 Sst2 C-terminal and PDZ ligand truncation mutants are expressed on the cell 
surface and can couple to Gi 
Sst2 is a Gi coupled GPCR that is activated by the endogenous ligand, somatostatin 
14 (SS14)(3, 51). After activation, the receptor is rapidly phosphorylated by G-
protein receptor kinases (GRKs), binds to β-arrestin, and undergoes clathrin-
dependent endocytosis (80, 83). Given that PDZ ligands and C-terminal motifs 
regulate trafficking for other GPCRs, we created two triple HA-tagged truncation 
mutants, one lacking the last 3 amino acids of the C-terminus (sst2 ΔTSI) and the 
other lacking the last 10 amino acids (sst2 358T) (Fig. 5A). We expressed these 
mutant receptors in HEK293 cells and measured their cell surface expression and 
their ability to inhibit cAMP production. We observed that the mutant receptors were 
expressed at the cell surface, although not to the same extent as the wild type 
receptor (Fig. 5C). We then asked if the differences in surface expression were due 
to the accumulation of intracellular receptor. Interestingly, sst2 358T exhibited very 
little intracellular expression. Sst2 ΔTSI exhibited a trend towards reduced 
intracellular expression, although this was not statistically significant (Fig. 5D). 
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These data suggest that the 10 C-terminal amino acids may play a role in retaining 
sst2 in intracellular compartments. To determine whether these mutant receptors 
were able to regulate cAMP production, we used the Promega Glosensor assay to 
measure whole cell cyclic AMP (cAMP) concentrations in cells treated with the 
forskolin analog NKH477 and SS14. We observed that both sst2 ΔTSI and sst2 
358T inhibited NHK477-induced cAMP accumulation in HEK293 cells (Fig. 5B), 
indicating that they couple as efficiently to Gi/o as the wild type receptor. The 
determination that the two sst2 mutants can reach the cell surface and couple to G 
proteins is consistent with the behavior of other GPCR mutants lacking their PDZ 
ligands, including LHR and β2AR (72, 124). 
Sst2 internalization and desensitization is regulated by multiple 
phosphorylation sites in the C-terminal tail that are upstream of the final 10 amino 
acids, including a serine cluster at amino acids 341 and 343 (Ser-341/343) and a 
threonine cluster at amino acids 353 and 354 (Thr-353/354). The serine cluster is 
important for desensitization, and the threonine cluster is required for β-arrestin 
recruitment and receptor internalization (79). Importantly, phosphorylation of GPCRs 
may be dependent on PDZ interactions. For example, phosphorylation of a third loop 
site of the beta-1 adrenergic receptor (β1AR) is dependent on an intact PDZ ligand 
and its interaction with SAP97 (128). Thus, we examined whether the sst2 C-
terminal truncation mutants could be phosphorylated at Ser-341/343 and/or Thr-
353/354 using previously validated phosphorylation-specific antibodies for sst2. We 
determined that both the serine and threonine clusters in each sst2 mutant were 
phosphorylated after treatment with SS14 to a similar extent as the wild type 
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receptor (Fig. 6). These data indicate that changes in C-tail phosphorylation are not 
responsible for altered behavior of the two sst2 mutants. 
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Figure 5:  Functionality of sst2 C-terminal mutants. A) Diagram of sst2 showing 
mutants lacking the last 3 (ΔTSI) or 10 C-terminal (358T) amino acids. B) HEK293 
cells were transfected with the Promega Glosensor 22F cAMP plasmid and sst2 
receptors. Cells were stimulated with the forskolin analog NKH477 (10 µM) alone, plus 
or minus SS14 (100 nM). Luminescence was normalized to cells stimulated with 
NKH477 alone and plotted to determine extent of cAMP inhibition for each receptor. 
Data are shown as the mean ± SEM for 3 independent experiments. C) Surface 
expression of sst2 ΔTSI and sst2 358T was measured by ELISA and compared to wild 
type receptor. Data are the mean ± standard error of the mean (SEM) of 3 independent 
experiments. D) Cell surface receptor levels were compared to total receptor by ELISA 
for sst2, sst2 ΔTSI and sst2 358T. Data are the average ± SEM of 3 independent 
experiments. (n.s. = not significant; * = p<0.05, ** = p<0.005). 
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3.2.2 The sst2 PDZ ligand and 10 C-terminal amino acids are not required for overall 
internalization and recycling 
Using a previously developed cell surface receptor ELISA, we examined the 
rate and extent of internalization and recycling of both sst2 ΔTSI and sst2 358T (80). 
HEK293 cells were transiently transfected with wild type sst2, sst2 ΔTSI, or sst2 
358T and treated for various times with a saturating concentration of SS14 (100 nM) 
to determine the extent of internalization. We hypothesized that the rate and extent 
of internalization would not be affected since both mutants can be phosphorylated at 
the threonine cluster responsible for β-arrestin binding and internalization (Fig. 6). 
Figure 6. C-tail phosphorylation of sst2 mutants. HEK293 cells were transfected 
with HA-tagged sst2, sst2 ΔTSI, or sst2 358T and stimulated with SS14 (100 nM) 
for 15 min. Lysates were probed with antibodies specific for the phosphorylation 
sites shown, and then reprobed for HA-epitope. 	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We observed that there were no significant differences in the rate or extent of 
internalization of sst2 ΔTSI or sst2 358T compared to wild type receptors (Fig. 7A). 
PDZ ligands often act as recycling signals for receptors. For example, the β1AR, 
β2AR, LHR, and kappa opioid receptors cannot efficiently return to the plasma 
membrane after ligand stimulation without binding to PDZ domain containing 
proteins (124, 128, 158, 159). We therefore hypothesized that sst2 ΔTSI and sst2 
358T would not recycle to the plasma membrane. Surprisingly, both sst2 mutants 
were able to recycle to the same extent and at the same rate as the wild type 
receptor (Fig. 7B). These data suggest that the PDZ ligand and 10 C-terminal amino 
acids of sst2 are not required for overall internalization or recycling.  
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Figure 7. Sst2 ΔTSI and sst2 358T internalize and recycle equally to wild type 
sst2.  A) HEK293 cells were transiently transfected with sst2, sst2 ΔTSI, or sst2 358T. 
The rate and extent of internalization after treatment with SS14 (100 nM) was 
measured using cell surface receptor ELISA. Values were normalized to untreated 
wells. Data are shown as the average ± SEM for 3 independent experiments. B) 
HEK293 cells were transiently transfected with sst2, sst2 ΔTSI, or sst2 358T. Cells 
were treated with SS14 (100 nM) for 30 min to induce maximal internalization of 
receptors. Agonist was then removed and fresh media containing 100 nM PRL2915 
(an sst2 specific antagonist) was added. Cells were allowed to recover for various 
times before fixation and cell surface receptor was normalized to untreated wells. Data 
are shown as the mean ± SEM for 3 independent experiments. There was no 
significant difference in the rate or extent of internalization or recycling for either mutant 
compared to wild type sst2, as determined by sum of squares F test. 	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3.2.3 The sst2 ΔTSI and sst2 358T mutants uncover receptor regulation by Rab4 
and Rab11 
As PDZ ligands can also affect intracellular trafficking without affecting the 
ability of a receptor to return to the plasma membrane, we determined if sst2, sst2 
ΔTSI, and sst2 358T were trafficked through the same pathways (75). Many 
receptors recycle through Rab4- or Rab11-positive compartments (112, 160). Thus, 
we contrasted the ability of dominant negative versions of Rab4 or Rab11 to affect 
recycling of wild type or mutant sst2 receptors at steady state.  We observed that co-
expression of dominant negative Rab4 or Rab11 did not affect wild type sst2 
internalization or recycling (Fig. 8A, B). The dominant Rab proteins were functional 
in this assay, as they inhibited recycling of the µOR (data not shown). On the other 
hand, expression of either dominant negative Rab4 or Rab11 inhibited the extent of 
sst2 ΔTSI recycling without affecting internalization (Fig. 8C, D). Interestingly, only 
expression of the Rab11 dominant negative protein inhibited sst2 358T recycling 
(Fig. 8E, F). These results suggest that while sst2 may be able to access numerous 
recycling pathways, sst2 ΔTSI recycling may be more limited and is dependent on 
the function of both Rab4 and Rab11 proteins. Similarly, sst2 358T is dependent on 
Rab11 protein function.  
 To confirm these observations, we assessed whether wild type and mutant 
sst2 receptors colocalized with GFP-Rab4- or GFP-Rab11-positive endosomes 
during recycling. We observed that wild type sst2 colocalizes with Rab4 and Rab11 
after 15 min of recycling (about the half-time of recycling) (Figs. 10 and 11). These 
data indicate that wild type sst2 can access both of these pathways, but is not 
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dependent on either for recycling. Surprisingly, sst2 ΔTSI and sst2 358T did not 
colocalize to the same extent with Rab4 as wild type sst2, indicating that the C-
terminus plays a role in trafficking sst2 into Rab4-positive endosomes (Figs. 10 and 
11). We did not find a significant change in colocalization with Rab11 for either 
mutant.  
Figure 8. Dominant negative versions of Rab4 and Rab11 inhibit recycling of sst2 
ΔTSI and sst2 358T, but not wild type sst2. (A, C, E) HEK293 cells were transiently 
transfected with GFP-tagged dominant negative mutants of Rab4 or Rab11 plus sst2 (A), 
sst2 ΔTSI (C), or sst2 358T (E). An empty GFP vector was used as a control. Cells were 
treated for 30 min with SS14 (100 nM). Cell surface receptor was measured by ELISA and 
compared to untreated controls. Data are shown as the mean ± SEM for 3 independent 
experiments. (B, D, F) Recycling of sst2 (B), sst2 ΔTSI (D), or sst2 358T (F) with Rab 
dominant negatives. Cells were transfected as in (A) and treated for 30 min with SS14 
(100 nM). Cells were then washed, fresh media with 100 nM PRL2915 was added, and 
the cells were incubated for 30 min. Cell surface receptor was measured by ELISA and 
compared to untreated controls. Data are shown as the mean ± SEM for 3 independent 
experiments (n.s. = not significant; * = p<0.05, ** = p<0.005). 
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Figure 9. Colocalization of sst2, sst2 ΔTSI, and sst2 358T with Rab4. A) HEK293 cells 
were transiently transfected with sst2, sst2 ΔTSI, or sst2 358T and GFP-Rab4. Cells were 
treated for 30 min with SS14 (100 nM), washed, fresh media with PRL2915 (100 nM) was 
added, and the cells were incubated for 15 min before being fixed and stained for 
immunofluorescence. Scale bars are 10 µm. B) Co-localization of sst2 and Rab4 during 
recycling. Data are the mean ± SEM for 3 independent experiments, with at least 6 cells 
quantified per experiment (**** = p<0.0001). 	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Figure 10. Colocalization of sst2, sst2 ΔTSI, and sst2 358T with Rab11. A) HEK293 
cells were transiently transfected with sst2, sst2 ΔTSI, or sst2 358T, and GFP-Rab11. 
Cells were treated for 30 min with SS14 (100 nM), washed, fresh media with PRL2915 
(100 nM) was added, and incubated for 15 min before being fixed and stained for 
immunofluorescence. Scale bars are 10 ìm. B) Co-localization of sst2 receptors and 
Rab11 during recycling. Data are the mean ± SEM from 3 independent experiments, with 
at least 6 cells quantified per experiment. (n.s. = not significant). 	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3.2.4 Sst2 traffics from early to late endosomes during endocytosis 
Sst2 is internalized from the plasma membrane into clathrin-coated pits and 
traffics into early endosomes shortly after stimulation with ligand. However later 
trafficking events of sst2 have not been well described (79, 81, 83).  Given that sst2 
recycling is not inhibited by dominant negative Rab11, we hypothesized that sst2 
was trafficking to late endosomes before being recycled to the plasma membrane.  
To assess whether this was the case, we determined the localization of wild type 
sst2 following SS14 stimulation using velocity gradient separation of endosomal 
organelles. We observed that sst2 is mostly colocalized with the early endosomal 
marker EEA1 after 2 min of agonist stimulation and is localized in both early and late 
endosomal fractions after 5 min stimulation. Thirty minutes after stimulation sst2 
moves into the late endosomal compartment (Fig. 11). Because our recycling assays 
begin after 30 min of SS14 stimulation, these data suggest that sst2 can recycle 
from late endosomal compartments. 
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Figure 11. Sst2 internalizes through early endosomes and traffics to late 
endosomes. HEK293 cells were transfected with HA-sst2 and treated for 2, 5, or 
30 min with SS14 (100 nM) to induce receptor internalization. Cells were lysed 
and endosome fractions were separated by centrifugation. Fractions were 
collected and analyzed by western blot. EEA1 is a marker for early endosomes 
and LAMP1 is a marker of late endosomes.	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3.2.5 The 10 C-terminal amino acids of sst2 are sufficient to dictate receptor 
recycling from late endosomes 
The delta opioid receptor (δOR) is a Gi-coupled GPCR that traffics from early to late 
endosomes after stimulation with ligand. However, after trafficking to late 
endosomes, δOR is degraded in lysosomes instead of recycling to the plasma 
membrane (70). The fate of δOR after endocytosis can be altered by adding 
recycling sequences to the C-terminal tail to create a chimeric receptor (126, 127). 
For example, replacing the 6 C-terminal amino acids of δOR with the 10 C-terminal 
amino acids of the β2AR or other class I PDZ ligands such as β1AR or the cystic 
fibrosis transmembrane receptor, alters the fate of receptor from lysosomal 
degradation to plasma membrane recycling. Importantly, removing the 6 C-terminal 
amino acids of δOR does not change its trafficking or degradation (127). To 
determine if the 10 C-terminal amino acids of sst2 can act as a recycling sequence, 
we created two δOR chimeras in which the last 6 amino acids of δOR were replaced 
with the 10 C-terminal amino acids of sst2 or 7 of the last 10 without the PDZ ligand 
(Fig. 12A).  We determined that these chimeras are expressed at the cell surface 
similarly to δOR (data not shown) and can couple equivalently to Gi to inhibit cAMP 
(Fig. 12B).  We then determined whether the C-terminal sst2 tail was sufficient to 
alter internalization or recycling. We observed that δOR, δOR sst2, and δOR sst2 
ΔTSI internalized to similar extents after 30 min of treatment with 1 µM DADLE, a 
specific δOR agonist (Fig 12C). For the recycling assays, cells were treated for 30 
min with 1 µM DADLE, washed, and 1 µM naloxone was added to block any residual 
agonist action. We observed that the δOR-sst2 and δOR sst2 ΔTSI chimeras 
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recycled to the plasma membrane more efficiently than δOR (Fig. 12D). These data 
suggest that additional determinants within 7 amino acids adjacent to the PDZ ligand 
are involved in regulating sst2 recycling. We also examined the intracellular 
localization of sst2 as compared to δOR in the same cells after treatment with both 
SS14 and DADLE for 30 min. Interestingly, δOR was almost completely localized in 
cytoplasmic puncta whereas sst2 was localized in both cytoplasmic puncta and a 
perinuclear compartment (Fig. 12E). This perinuclear compartment may be the TGN, 
as sst2 is found in the TGN in ligand stimulated HEK293 cells and primary neuronal 
cultures (82, 85, 154). These data indicate that the C-terminus of sst2 acts as a 
sorting signal, most likely at the late endosome, and is sufficient to direct recycling of 
a heterologous receptor. 
  
Figure 12. The 10 C-terminal amino acids of sst2 are sufficient for receptor 
recycling from late endosomes. A) Diagram depicting amino acid changes for the 
δOR chimeras. B) Effects of δOR, δOR sst2, or δOR sst2 ΔTSI stimulation on cAMP 
levels as measured using the Promega Glosensor cAMP assay. HEK293 cells were 
transiently transfected with receptor (or empty vector as a control) and the Glosensor 
22F plasmid. Cells were stimulated with the forskolin analog NKH477 (10 µM) alone or 
plus the δOR agonist DADLE (1 µM). Data are normalized to NKH477 treatment alone 
and plotted as the mean ± SEM from 3 independent experiments. C) Internalization of 
the δOR chimeras was measured using cell surface ELISA. D) Recycling of δOR 
chimeras. HEK293 cells were transiently transfected with the receptors shown, treated 
for 30 min with 1 µM DADLE, washed, and incubated in fresh media with the δOR 
antagonist naloxone (1 µM) for 30 min. Data are plotted as the extent of recycling. E) 
HEK293 cells were transiently transfected with HA-sst2 and FLAG-δOR and treated for 
30 min with both SS14 (100 nM) and DADLE (1 µM) to induce internalization. Cells 
were fixed and stained for immunofluorescence. The Pearson’s correlation coefficient 
for colocalization sst2 and δOR receptors was 0.69± 0.02 (mean ± SEM) for at least 6 
cells per experiment from 3 independent experiments. Scale bar is 10 ìm. (n.s. = not 
significant, **:p<0.005, ****: p<0.0001). 
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3.2.6 The C-terminal tail of sst2 targets it to the trans-golgi network  
As our results indicate that sst2 recycles from the late endosome and that the 10 C-
terminal amino acids are sufficient for recycling, we hypothesized that the 10 C-
terminal amino acids of sst2 direct trafficking from late endosomes to the TGN to 
allow recycling to the plasma membrane. Sst2 has previously been shown to 
colocalize with the cation-independent mannose-6-phosphate receptor (CI-M6PR), a 
TGN marker, after treatment with 100 nM SS14 in HEK293 cells(82). Thus, we used 
confocal microscopy to assess whether sst2 ΔTSI or sst2 358T co-localized with CI-
M6PR after 30 min of treatment with 100 nM SS14. We observed that significantly 
less sst2 358T colocalized with the CI-M6PR (Fig 13A, B), suggesting that the 10 C-
terminal amino acids direct sst2 to the TGN.  
 
3.2.7 Sst2 budding from late endosomes is dependent on retromer components 
Late endosome to TGN trafficking is usually dependent on retromer components 
(115). To determine whether sst2 budding from the late endosome is retromer-
dependent, we used a cell-free assay that measures the budding of vesicles from 
late endosomal membranes and is dependent on cytosolic factors (146, 151). In this 
assay endosomes are separated by density gradient centrifugation, and late 
endosomes can then be incubated with ATP and either complete yeast cytosol or 
yeast cytosol lacking individual trafficking proteins (Fig. 13C). Thus, this assay takes 
advantage of the homology between yeast and human trafficking proteins to allow 
one to unequivocally identify proteins are that required for endosomal budding. Cells 
transfected with sst2 were stimulated with SS14 30 min, lysed, and endosomal 
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membranes were isolated. We then examined whether sst2 was capable of budding 
from late endosomal membranes. We also determined whether cytosol lacking 
SNX1/2, which is a component of the retromer complex, affected sst2 budding. We 
observed that wild type cytosol supported significant budding of sst2 from the late 
endosomal fraction, but that significantly less budding of sst2 occurred when using 
the cytosol lacking SNX1/2 was used (Fig 13D). The dependence of sst2 budding on 
retromer components is consistent with the observation that sst2 traffics to the TGN. 
Overall, our data indicate that sst2 is internalized into early endosomes, traffics to 
late endosomes, and buds from the late endosome in a retromer-dependent fashion, 
presumably to allow movement to the TGN and ultimately recycling to the plasma 
membrane. Moreover, the 10 C-terminal amino acids of sst2 appear to be sufficient 
for recycling from late endosomes and help direct the receptor to the TGN. 
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Figure 13. Sst2 trafficking from the late endosome to the trans-golgi network is 
dependent on the last 10 C-terminal amino acids and the retromer complex. A) 
HEK293 cells were transiently transfected with HA-tagged sst2, sst2 ΔTSI, or sst2 
358T, treated with SS14 (100 nM) for 30 min, and fixed. Cells were co-stained for 
HA-epitope (green) and M6PR (red) to mark the trans-golgi network. Scale bars are 
10 ìm. B) Colocalization of M6PR and sst2 mutants. Data are the mean ± SEM for 6 
cells per experiment from 3 independent experiments. Pearson’s correlation 
coefficient (PCC) for the two sst2 mutants was compared to sst2 (p = 0.12 for sst2 
ÄTSI; p = 0.0045 for sst2 358T). C) Diagram of in vitro endosome sorting assay. 
Cells expressing HA-sst2 were treated with SS14 (100 nM) for 30 min to allow 
receptors to internalize and reach late endosomes. Cells were then mechanically 
lysed and the endosomal fractions were separated by centrifugation through a 
continuous gradient. The late endosome fractions were collected and incubated with 
either complete or ΔSNX1/2 yeast cytosol for 3 hours at 37°C to allow for receptor 
budding from the endosomes. The mixture was then centrifuged to pellet the heavier 
multivesicular bodies and the supernatant was collected, pelleted, dissolved in 
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sample buffer, and resolved by SDS- PAGE to determine the extent of receptor 
budding. D) Quantification and representative western blots of sst2 budding after 
incubation with complete or ΔSNX1/2 yeast cytosol. Quantification is mean ± SEM 
for 3 independent experiments, with budding from endosomes incubated with 
complete yeast cytosol set as 1.0. (n.s. = not significant, *: p<0.05, **:p<0.005). 
 
3.2.8 The sst2 PDZ ligand alters sst2 trafficking in somatolactotroph cells 	   We hypothesized that the differences we see in intracellular trafficking 
between sst2 and sst2 ΔTSI could be more pronounced in cell lines other than 
HEK293 cells with differing trafficking machinery. We measured the rate and extent 
of internalization and recycling of sst2 and sst2 ΔTSI in GH12C1 cells, a cell model of 
somatolactrotroph tumor cells (Fig 14). Interestingly, we found differences in both 
the extent of internalization and the rate of recycling between sst2 and sst2 ΔTSI. 
Given that sst2 can access numerous pathways to recycle to the plasma membrane, 
the specific trafficking machinery present in a given cellular environment dictates 
which of those pathways sst2 can access. 	    
	   66	  
	  
	  	  	  	  	  	  	  	  	  	  
0 20 40 60
0
20
40
60
80
100
Time (min)
C
el
l S
ur
fa
ce
 re
ce
pt
or
 (%
) GH12C1 Internalization
sst2
sst2 ΔTSI 
0 20 40 60
0
20
40
60
80
100
Time (min)
C
el
l S
ur
fa
ce
 re
ce
pt
or
 (%
) GH12C1 Recycling 
sst2 
sst2 ΔTSI 
A B
Figure 14. The sst2 PDZ ligand alters recycling in somatolactotroph cells. 
A) GH12C1 stably expressing either sst2 or sst2 ΔTSI were treated for various 
times with SS14 (100nM). The rate and extent of internalization was measured 
using cell surface receptor ELISA. Values were normalized to untreated wells. 
Data are shown as the average ± SEM for 3 independent experiments. B) 
GH12C1 cells stably expressing either sst2 or sst2 ΔTSI were treated with SS14 
(100 nM) for 30 min to induce maximal internalization of receptors. Agonist was 
then removed and fresh media containing 100 nM PRL2915 (an sst2 specific 
antagonist) was added. Cells were allowed to recover for various times before 
fixation and cell surface receptor was normalized to untreated wells. Data are 
shown as the average ± SEM for 3 independent experiments. There was no 
significant difference in the rate of internalization however there was a 
significant difference in the extent. Sst2: 33.7±3.3%, sst2 ΔTSI: 45.5±3.1%, 
p=0.0013. While both sst2 and sst2 ΔTSI were able to fully recycle to the 
plasma membrane, sst2 ΔTSI recycled significantly faster. t1/2 for sst2: 13.1±2.1 
min, sst2 ΔTSI: 5.1±0.7 min., p=0.0003. 
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3.2.9 TAT Peptide Design 
Given that subtle differences in receptor levels can affect sst2 signaling, we 
designed cell permeable peptides to allow us to evaluate changes in signaling in a 
signal clonal cell line. These peptides allow us to use the same clonal cells lines to 
evaluate how sst2 PDZ ligand-protein interactions affect signaling pathways. The 
peptides have two portions, the TAT sequence that allows the peptide to enter the 
cell and the 10 C-terminal amino acids to block PDZ interactions. 
The sst2 specific peptide (TAT-SST2): GRKKRRQRRRPPQGGGLLNGDLQTSI 
The control peptide (TAT-AAA): GRKKRRQRRRPPQGGGLLNGDLQAAA 
 
3.2.10 The sst2 PDZ ligand does not alter G-protein coupling 
Using a live, whole cell cAMP assay, we asked if the sst2 PDZ ligand altered 
the ability for sst2 to couple to Gi/Go proteins and inhibit cAMP. We showed that 
both sst2 ΔTSI and sst2 358T inhibit cAMP accumulation if stimulated with 
saturating concentrations of SS14 (Fig 5B). We also asked if a loss of PDZ ligand-
domain interactions shifts the dose response curve to SS14 as a subtle difference is 
G-protein coupling may not be seen with saturating concentrations of SS14. We 
found no difference in the dose-response curve to SS14 between cells stably 
expressing sst2 or sst2 ΔTSI. We also did not find a difference when PDZ ligand-
domain interactions were blocked with TAT peptides. This data indicates that the 
PDZ ligand is not required for Gi/Go coupling and cAMP inhibition. 
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Figure 15. The sst2 PDZ ligand does not affect the inhibition of cAMP. A) 
HEK293 cells stably expressing either sst2 or sst2 ΔTSI were transiently 
transfected with Promega Glosensor plasmid. Cells were treated with 10µM 
NKH477 and various concentrations of SS14 and luminescence was 
measured. Data are plotted as the % of maximal luminescence with NKH477 
alone. A representative curve of 3 independent experiments is shown. B) Cells 
stably expressing both sst2 and the Promega Glosensor plasmid were treated 
with either TAT-AAA or TAT-SST2 for 30 min prior to the experiment. Cells 
were treated with 10µM NKH477 and various concentrations of SS14 and 
luminescence was measured. Data are plotted as the % of maximal 
luminescence with NKH477 alone. A representative curve of 3 independent 
experiments is shown. 
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3.2.11 The sst2 PDZ ligand is not required for potassium channel activation 
 Sst2 can activate potassium channels leading to membrane 
hyperpolarization. This hyperpolarization leads the inhibition of voltage gated 
calcium channels and a subsequent decrease in intracellular calcium. The decrease 
in intracellular calcium leads to an inhibition of hormone secretion. We asked if the 
sst2 PDZ ligand was necessary for the activation of potassium channels. We used 
GH12C1, a somatotroph cell line that stably express sst2, and determined if PDZ 
interactions changed the membrane hyperpolarization after stimulation with SS14. 
Using the FLPR membrane dye, we determine that there is no difference in maximal 
membrane hyperpolarization if PDZ interactions are blocked compared to control. 
There was also no difference in the time course of activation. This is likely due to 
potassium channels being activated by Gi/Go proteins as the activation is PTX 
sensitive and we do not see a shift in the dose response curve for cAMP inhibition 
when PDZ interactions are blocked.  
 
3.2.12 The sst2 PDZ ligand is not required for calcium inhibition 
Activation of sst2 leads to membrane hyperpolarization and a subsequent 
inhibition of voltage gated calcium channels. This leads to a decrease in intracellular 
calcium and the inhibition of hormone secretion. We asked if blocking PDZ 
interactions would alter sst2’s ability to decrease intracellular calcium. Fluo-8 AM is a 
fluorescent calcium indicator dye, using this assay we measured relative intracellular 
calcium before and after sst2 stimulation. We found no difference in the intracellular 
calcium decrease when PDZ interactions are blocked. This is consistent with our 
	   70	  
observations that PDZ interactions do not alter Gi/Go coupling or potassium channel 
inhibition. It is possible that the PDZ ligand is not required for the mechanisms that 
cause an acute inhibition of hormone secretion. 
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Figure 16: The sst2 PDZ ligand is not required for membrane hyperpolarization 
or calcium channel inhibition. A) GH12C1 cells stably expressing sst2 were treated 
with TAT-AAA or TAT-SST2 for 30min prior to the experiment. Cells were treated 
with SS14 (100nM) and membrane polarization was measured with FLIPR 
membrane dye. Fluorescence was normalized to untreated wells. Data shown is a 
representative experiment. There was no difference in membrane hyperpolarization 
between TAT-AAA and TAT-SST2. Data shown is a representative trace from 3 
independent experiments. B) GH12C1 cells stably expressing sst2 were treated with 
TAT-AAA or TAT-SST2 for 30min prior to the experiment. Cells were treated with 
SS14 (100nM) and intracellular calcium was measured with Fluo8. Fluorescence was 
normalized to untreated cells. Data shown is a representative experiment. There was 
no difference in intracellular calcium inhibition between TAT-AAA and TAT-SST2. 
Data shown is a representative trace from 3 independent experiments. 
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3.2.13 The sst2 PDZ ligand does not alter ERK/MAPK activation 
 Depending on the cellular context, sst2 can either activate or inhibit the 
ERK/MAPK pathway. In HEK293 cells, sst2 can activate the ERK/MAPK pathway in 
both a PTX sensitive and PTX insensitive manner. The activation occurs rapidly, 
peaks between 2 and 5 min, and returns to baseline activation levels by 10 min. 
Although not as strong of a total activation, the PTX insensitive component also has 
the same pattern of activation. As PDZ ligand-domain interactions can affect both 
the total activation and the time course of activation of the ERK/MAPK pathway, we 
asked if the sst2 PDZ ligand affected sst2’s ability to activate the ERK/MAPK 
pathway. Two mechanisms allow for PDZ interactions to affect ERK signaling: one is 
the direct scaffolding of receptors to components of the ERK pathway such as 
GRB2, and the other is through altered trafficking of receptors which typically alters 
the time course of ERK signaling(72, 156). We hypothesized that we would see a 
change in the PTX insensitive component, as we do not see changes in the Gi/Go 
coupling when PDZ interactions are blocked. HEK293 cells stably expressing sst2 
were preincubated with the specific or control TAT peptide, and then stimulated with 
SS14 for the times indicated, and placed on ice, and phospho-ERK levels were 
determined using western blot. Our data was consistent with the published data, 
ERK activation peaked at 2 min and was near baseline by 10 min. Additionally, this 
time course was the same for both the PTX sensitive and insensitive component of 
activation consistent with the literature. We did not find any difference in either the 
extent of activation nor the time course between the control and when PDZ 
interactions are blocked. This is consistent with our findings that PDZ interactions 
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are not required for Gi/Go coupling. The mechanisms of PTX insensitive ERK 
activation have yet to be elucidated but we conclude that PDZ interactions are not 
required for this component of activation either. 
 
 
Figure 17. The sst2 PDZ ligand is not required for ERK activation. A) 
Representative western blot. HEK293 cells stably expressing sst2 were pretreated 
with TAT-AAA or TAT-SST2 and then with SS14 (100nM) for various time points. 
pERK and total ERK were measured by western blot. B) Quantitation of three 
independent experiments of (B). There was no difference in the rate or extent of 
ERK activation. C) Representative western blot. HEK293 cells stably expressing 
sst2 were treated with pertussis toxin overnight. They were then pretreated with 
TAT-AAA or TAT-SST2 and then with SS14 (100nM) for various time points. pERK 
and total ERK were measured by western blot. D) Quantitation of three independent 
experiments of (C). There was no difference in the rate or extent of ERK activation. 
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3.3 Discussion 
Endocytic sorting is a major mechanism of GPCR regulation and plays a role 
in determining the strength, localization, and specificity of signaling. Many GPCRs 
use a complex method of sequence-directed intracellular trafficking that relies on the 
receptor being able to interact with various cytoplasmic proteins. This method of 
trafficking allows for a receptors’ fate to be determined at multiple points along an 
intracellular pathway. Before this study, little was known about the motifs of sst2 that 
regulate its endocytic sorting. We have demonstrated that the sst2 PDZ ligand and 
10 C-terminal amino acids direct the receptor into various endosomal compartments. 
We initially hypothesized that the PDZ ligand was required for sst2 plasma 
membrane recycling but surprisingly found that neither the PDZ ligand nor the 10 C-
terminal amino acids were required. Thus we assessed whether sst2 undergoes 
sequence-directed endocytic sorting, in part determined by the PDZ ligand motif.  
Prior studies have demonstrated that sst2 can traffic to the TGN after ligand 
stimulation, and then recycle rapidly to the plasma membrane (80, 82). Given that 
there are many pathways that receptors can utilize to recycle, we asked if sst2 could 
access some of the better described endocytic recycling pathways, including those 
regulated by Rab4 and Rab11. Our data was surprising in that wild type sst2 
localized to Rab4-positive endosomes during recycling to a greater degree than of 
either sst2 mutant, despite the fact that the Rab4 dominant negative did not affect 
wild type sst2 recycling. It was similarly interesting in that the dominant negative 
Rab11 blocked overall recycling of both sst2 mutants but did not affect wild type sst2 
recycling. While initially this data may seem contradictory, it is consistent with the 
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idea that wild type sst2 can follow multiple endocytic trafficking pathways depending 
on its interaction with distinct cytoplasmic trafficking proteins, and that blocking any 
one pathway is not sufficient to prevent receptor recycling.  It follows that deletion of 
C-terminal residues within sst2 limits the spectrum of trafficking proteins with which 
the receptor can interact, thereby uncovering a dependency on Rab4 or Rab11 not 
observed with the wild type receptor. Our data also indicates that the PDZ ligand 
directs sst2 to the TGN during endocytic trafficking, and that sst2 undergoes 
retromer dependent sorting. These data are consistent with the idea that sst2 
undergoes sequence-directed endocytic sorting which is regulated at multiple steps. 
An outstanding question is if the sst2 PDZ ligand plays a role in signaling. 
The two main mechanisms of sst2’s ability to inhibit hormone secretion are 
through the acute inhibition of cAMP and the activation of potassium channels 
leading to inhibition of calcium channels and a subsequent drop in intracellular 
calcium(Fig 2). As both of these mechanisms are dependent upon Gi/Go signaling, 
our data is consistent in that if there is no change in Gi/Go coupling when PDZ 
interactions are blocked, we should not see any change in either cAMP inhibition of 
potassium channel activation. Additionally, this is consistent with the fact that we do 
not see a change in intracellular calcium inhibition, as this is dependent on 
potassium channel activation and membrane hyperpolarization. This data is also 
consistent with our data showing no effect on ERK signaling. The pertussis toxin 
sensitive component of ERK signaling is also dependent on Gi/o proteins. However, 
how sst2 signals to the ERK/MAPK pathway in a PTX insensitive manner is still 
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unknown. Although the mechanism is still unknown, it is unlikely that this signaling is 
dependent upon an intact PDZ ligand. 
One important caveat to our findings is that PDZ proteins may scaffold sst2 to 
ion channels for more efficient signaling. Unfortunately, the time course of activation 
of ion channels may be too rapid for us to parse out small changes in the time 
course of channel activation using either the membrane polarization or calcium dyes. 
A more sensitive method, such as electrophysiology may be required to understand 
if there are more subtle changes that occur through protein scaffolding.   
An important outstanding question is whether sequence directed trafficking 
affects sst2 signaling. Signaling by other GPCRs has been shown to be altered by 
subtle changes in receptor trafficking. For example, PTHR1 can traffic through at 
least two different pathways depending on PDZ interactions, a rapid recycling 
pathway and a slower, retromer-dependent pathway. Importantly, the rapid recycling 
pathway is crucial for the effect of PTHR1 on bone development (161). Although it 
has yet to be determined if sst2 can signal intracellularly, it’s possible that sst2 
traffics through various endocytic pathways to enable different signaling outcomes. It 
is further possible that alterations in trafficking-dependent signaling could contribute 
to variations in tumor responses to somatostatin analogs. Futures studies will be 
necessary to answer these important questions and to continue to fully uncover the 
mechanisms that regulate sst2 intracellular trafficking. 	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Chapter 4 
SHANK3 increases sst2 surface expression in an isoform specific manner 
 
4.1 Introduction 
The SHANK family of proteins consists of 3 members, SHANK1, SHANK2, 
and SHANK3(92, 134, 139). These proteins are large neuronal scaffolding proteins 
that are expressed highly through the central nervous system and in various tissues 
throughout the rest of the body(141, 162, 163). They play critical roles in numerous 
neuronal processes including actin/cytoskeleton remodeling, AMPA receptor 
endocytosis, synapse formation, glutaminergic transmission, and synaptic 
plasticity(135, 138, 164). The role of SHANK proteins in disease was first recognized 
when the deletion of SHANK3 was determined to be the cause of intellectual 
disability in Phelan-McDermind Syndrome(136). Since then, deletions, duplications, 
and mutations of all three SHANK proteins have been associated with several 
neuronal diseases including autism, schizophrenia, and bipolar disorder(135, 137, 
144).  
All three proteins have the same basic structure including N-terminal ankyrin 
repeats, an SH3 domain, a PDZ domain, a large proline rich region, and a C-
terminal sterile alpha motif (SAM domain)(Fig 4). Numerous protein-protein binding 
domains allows for SHANK proteins to bind to many other proteins including other 
scaffolding proteins, receptors, ion channels, and small GTPases, amongst others to 
create macromolecular complexes for rapid and specific signaling(135). 
Interestingly, there are many common binding partners amongst the three SHANK 
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proteins although the degree of functional overlap of the three proteins has yet to be 
determined.  
Adding to the complexity, each SHANK protein has multiple promoters and 
can be differentially spliced leading to a wide variety of isoforms of all three 
proteins(143). There is data demonstrating that specific isoforms have specific 
functions, such as the requirement of the SAM domain for synaptic targeting of 
SHANK2 and SHANK3, however work still needs to be done to understand tissue 
specific isoform expression as well as the functional effect of each isoform(165). The 
SAM domain also allows for SHANK3 to scaffold to itself and is thought to be crucial 
for organization of the post-synaptic density(166). There is some clinical data 
suggesting that certain isoforms play specific signaling roles. Numerous mutations in 
SHANK1, 2 and 3 have been implicated in schizophrenia and bipolar disorder. 
These mutations are only present in specific isoforms indicating that alternative 
isoforms or the other members of the SHANK family cannot compensate for the loss 
of function(144).  
 In this study, we determined that SHANK3 binds to sst2 through a PDZ 
ligand-domain interaction similarly to SHANK1 and SHANK2. We asked whether this 
interaction was clinically relevant by determining if normal neuroendocrine tissue 
such as pituitary expresses the various SHANK family members and if this 
expression is altered in neuroendocrine tumors. We found that 
 while SHANK proteins are expressed in normal neuroendocrine tissues such as the 
pituitary, their expression is often altered in an unpredictable pattern in 
neuroendocrine tumors. Most importantly, we were able to determine that SHANK3 
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expression increases the surface expression of sst2. This function requires the 
expression of the full-length isoform of SHANK3, as SHANK3 truncation mutants 
were not able to increase the cell surface expression of sst2. These data suggest 
that SHANK3 plays an isoform specific role in sst2 membrane expression. Alteration 
of SHANK3 expression in neuroendocrine tumors could lead to changes in sst2 
expression and therefore affect the tumors response to octreotide. 
 
4.2 Results 
4.2.1 SHANK1, SHANK2, and SHANK3 bind to sst2 through the PDZ ligand 
SHANK1 and SHANK2 had previously been shown to bind to sst2 through a 
PDZ ligand/domain interaction. SHANK1 and 2 were initially identified as sst2 
binding partners using a yeast-2-hybrid assay where the sst2 C-terminal tail was the 
bait and a rat brain cDNA library was the prey(88). They identified SSTRIP and 
CortBP1 as sst2 interactors, which were renamed SHANK1 and SHANK2. 
Additionally, they confirmed that it was specifically the PDZ domain of both SHANK1 
and SHANK2 that bound to the C-tail of sst2 using GST overlay assays. We were 
able to confirm that the PDZ domains of SHANK1 and SHANK2 bind specifically to 
sst2 using a biotinylated-peptide pulldown assay. However, SHANK3, which has an 
almost identical PDZ domain as SHANK1 and SHANK2, has not been shown to bind 
to sst2. We hypothesized that SHANK3 would also bind to sst2 through the PDZ 
domain. We found that SHANK1, 2, and 3 all bind specifically to the last 10 amino 
acids of sst2 using a biotinylated peptide pulldown assay (Fig 18). None of the 
SHANK proteins bound to the peptide where the last three amino acids of sst2 were 
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mutated from TSI to AAA to disrupt PDZ binding. These results indicate that all three 
SHANK proteins bind to sst2 through a specific PDZ ligand-domain interaction. 
These results indicate that sst2 should be able to interact with SHANK protein 
isoforms that contain a PDZ domain, although this would have to be confirmed for 
each individual isoform. Additionally, some proteins such as mGluR5, can interact 
with SHANK3 through both a direct interaction with the PDZ domain and through an 
indirect scaffolding intermediate that binds to the proline rich region of 
SHANK3(140). We have yet to determine if the interaction with sst2 is solely through 
the PDZ domain or could also be through an addition protein.  
 
 
 
 
 
 
 
 
Figure 18: All three SHANK PDZ domains bind specifically to the PDZ ligand of 
sst2. 
HEK293 cells were transiently transfected with FLAG tagged SHANK PDZ domains 
and the lysates were used in a biotinylated peptide pulldown. The bait was the 10 C-
terminal amino acids of sst2 (TSI) or the last 10 but with the final 3 amino acids 
mutated to alanines (AAA) to disrupt PDZ binding. 	  
	   80	  
4.2.2 SHANK protein expression in rat pituitary and pituitary tumor cell lines 
 SHANK2 and SHANK3 are highly expressed in the cortex and have also been 
shown to be expressed in rat pituitary somatotrophs(145). There are numerous 
different isoforms of both SHANK2 and SHANK3 and tissue specific expression of 
these various isoforms of SHANK proteins have yet to be described. As we did not 
know if the pituitary expressed isoforms of SHANK3 that contained a PDZ domain, 
we used RT-PCR and specific primers to amplify the PDZ domain of SHANK1, 2, or 
3. Rat cortex and pituitary was harvested from Sprague Dawley rats to determine the 
tissue specific expression of SHANK proteins. We also examined if two cells line 
models of pituitary tumors expressed SHANK isoforms with PDZ domains. GH4C1 
cells are a somatolactroph cell line derived from a spontaneous rat pituitary tumor 
and secrete both growth hormone and prolactin(167). They express both sst2 and 
sst5, which we were able to confirm by RT-PCR (Fig 19A), and respond to SS14 and 
SAs. Additionally, we determined if AtT20 cells, a cell model of corticotroph tumors 
derived from a mouse tumor, expressed SHANK proteins. AtT20 express both sst2 
and sst5, secrete ACTH, and respond to SS and SAs. Cortex was used as a positive 
control for both rat and mouse cells lines as all three SHANK proteins are 
expressed. Interestingly, only SHANK2 and SHANK3 are expressed in normal rat 
pituitary and only SHANK3 in GH4C1 cells, although additional isoforms lacking the 
PDZ domains could be present.  This is in comparison to AtT20 cells which express 
SHANK1 and SHANK2. Unfortunately this assay is limited, as we cannot determine 
which specific cell types within the pituitary express different SHANK proteins and is 
also limited to only detecting isoforms that contain the PDZ domain. 
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Figure 19. SHANK expression in neuroendocrine cell lines. A) SHANK 
expression in pituitary tumor cell lines. Primers were designed to amplify the PDZ 
domains of the three SHANK proteins by RT-PCR. Expression in tumor cell lines 
were compared to rat pituitary. Rat or mouse cortex was used as a positive 
control. No reverse transcriptase controls were run but not shown here. Eef2 was 
used as a housekeeping control. B) SHANK expression in human gastrointestinal 
and pancreatic neuroendocrine tumor cells lines. Primers were designed to 
amplify the PDZ domains of the three SHANK proteins by RT-PCR. No reverse 
transcriptase controls were run but not shown here. Eef2 was used as a 
housekeeping control. 
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4.2.3 SHANK expression in human neuroendocrine tumor lines  
 There are several cell line models of neuroendocrine tumors that are derived 
from human tumors although none of these are derived from pituitary tumors. 
CNDT2.5 cells are a model of gastrointestinal neuroendocrine tumors(168). These 
cells were derived from a liver metastasis from a patient with a primary ileal 
carcinoid tumor, secrete serotonin, and express sst2.  BON cells are another model 
of gastrointestinal NETs, although were derived from a pancreatic carcinoid 
tumor(169). The cell type of origin is particularly important for NETs as tumors 
derived from different cell types behave differently. Using RT-PCR and primers to 
specifically amplify the PDZ domains of the three SHANK proteins, we found that 
CNDT2.5 express SHANK1, 2, and 3 whereas BON cells do not express any of the 
three SHANK proteins. IMR32 cells, a neuroblastoma cell line, were used as a 
positive control as they have been shown to express all three SHANK proteins(142). 
SHANK expression in HEK293 cells was also examined (Fig 19B).  Again, this assay 
is limited as we only looked for isoforms containing the PDZ domain. Additionally, 
cells within the diffuse neuroendocrine system are such as small fraction of the total 
cells within the gastrointestinal system or pancreas, we do not have the ability to 
examine SHANK expression in normal neuroendocrine cells. It is interesting to note 
that different types of neuroendocrine cell lines have different SHANK protein 
expression. It is possible that sst2’s interaction with SHANK family members or other 
PDZ proteins allows for cell type specific regulation by sst2.  
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4.2.4 SHANK protein expression is altered in human pituitary tumors 
As there is expression of SHANK proteins in pituitary tissue and all three 
SHANK proteins can bind to sst2, we hypothesized that SHANK proteins could play 
a role in sst2 regulation and response to SAs in human pituitary tumors. We first 
asked if SHANK proteins were expressed in normal human pituitary using primers to 
amplify the PDZ domains. Interestingly, we found that the expression of SHANK 
proteins in normal human pituitary differs from that of rat pituitary. We found that 
SHANK1 and 3 are expressed in human whereas SHANK2 and 3 were expressed in 
rat. Additionally, we determined the expression of SHANK proteins in four different 
types of human pituitary tumors: GH, ACTH, or PRL secreting along with non-
functioning adenomas.  Although we could not correlate our data with the response 
to SAs, we found that pituitary tumors have variable expression of all three SHANK 
proteins (Table 2). The alteration of the various SHANK proteins in pituitary tumor 
could potentially effect regulation of sst2.  
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   sst2	   SHANK1	   SHANK2	   SHANK3	  	  
Normal	  
Pituitary	   6/6	   6/6	   0/6	   5/6	  
Non-­‐
Functioning	  
Adenomas	   30/30	   29/30	   12/30	   20/30	  
GH	  Secreting	   12/13	   7/13	   5/13	   8/13	  
ACTH	  
Secreting	   3/3	   3/3	   1/3	   2/3	  
PRL	  
Secreting	   1/2	   2/2	   2/2	   0/2	  
 
4.2.5 SHANK3 increases plasma membrane expression of sst2. 
 We have shown that the loss of the PDZ ligand or 10 C-terminal amino acids 
decreases the amount of sst2 present on the plasma membrane (Fig 5C). 
Interestingly, we found that co-expressing sst2 and SHANK3, increases the amount 
of sst2 present on the plasma membrane. This effect is also specific for SHANK3, as 
co-transfecting sst2 and SHANK1 did not increase sst2 surface expression(Fig 20A).  
 This effect is also independent of the PDZ ligand of sst2 as expression of SHANK3 
increased the plasma membrane expression of both sst2 ΔTSI and sst2 358T (Fig 
20B). It is possible that SHANK3 can bind to sst2 through additional sites. 
Additionally, it is possible that the effect on plasma membrane expression does not 
require direct binding. Expression of SHANK3 could allow for increased expression 
of sst2 at the plasma membrane either through indirect binding to sst2 through an 
Table 2: SHANK expression in human pituitary samples. SHANK and sst2 
expression in human pituitary tumor samples was determined by PCR. Primers 
were designed to amplify the PDZ domains of the various SHANK proteins. 
Results were compared to normal human pituitary. 	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intermediate such as cortactin or through a mechanism such as altering endosomal 
dynamics. 
 
 
Figure 20. SHANK3 increases cell surface expression of sst2. A) HEK293 cells 
were co-transfected with HA tagged sst2 and either SHANK3, SHANK1, or an empty 
vector used as a control. Receptor cell surface expression was measured by ELISA 
and normalized to the surface expression of sst2 with the vector control. Data are 
the average± SEM of three independent experiments. B) SHANK3 increases cell 
surface expression independent of the PDZ ligand. HEK293 cells were co-
transfected SHANK3 and HA tagged sst2, sst2 ΔTSI, or sst2 358T. Receptor cell 
surface expression was measured by ELISA and normalized to the surface 
expression of sst2 with the vector control. (n.s.=not significant, *=p<0.05, 
***=p<0.0005). 
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4.2.6 The SAM domain of SHANK3 is required for increased expression of sst2 
 We created two truncation mutants of SHANK3 to understand if the full-length 
isoform of SHANK3 or certain binding domains are required for the effect on sst2 
plasma membrane expression. The SAM domain of SHANK3 has been shown to be 
required for synaptic targeting and SHANK3 isoforms that lack the SAM domain 
often are localized in the nucleus(165). We hypothesized that the SAM domain was 
required for the effect of surface expression of sst2. One truncation mutant lacked 
just the SAM domain and the second lacked both the SAM domain and the cortactin 
binding region in the proline rich region(Fig 21A). The cortactin binding domain was 
removed as binding to cortactin is one of the major ways the SHANK3 organizes 
protein-complexes. Cortactin allows SHANK3 to interact with the actin-cytoskeleton 
and has functions in SHANK3 regulation of protein trafficking leading us to 
hypothesize that cortactin could play a role in sst2 cell surface expression(166). We 
also tested if the PDZ domain was sufficient to increase cell surface expression. We 
found that co-expressing the PDZ domain of SHANK3 was not sufficient to increase 
cell surface expression of sst2 (Fig 21C). Interestingly, we found that only the full 
length SHANK3 construct increases sst2 plasma membrane expression. Neither 
SHANK3 1448T, nor SHANK3 1334T was able to increase sst2 expression 
compared to co-expressing an empty GFP construct (Fig 21D).  
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 Figure 21. The SAM domain is required for increased cell surface of sst2 by 
SHANK3. A) Cartoon depicting the protein-protein binding domains present in the 
various SHANK clones. B) Western showing expression of the three SHANK clones. 
C) HEK293 cells were co-transfected with sst2 and a clone expressing only the PDZ 
domain of SHANK3 or an empty vector control. Receptor cell surface expression 
was measured by ELISA and normalized to the surface expression of sst2 with the 
vector control. Data are the average ± SEM of three independent experiments. D) 
HEK293 cells were co-transfected with sst2 and a full length SHANK3, a truncation 
mutant lacking the SAM domain (1448T), or a truncation mutant lacking the SAM 
domain and part of the proline-rich region. Receptor cell surface expression was 
measured by ELISA and normalized to the surface expression of sst2 with the vector 
control. Data are the average ± SEM of three independent experiments. (n.s.=not 
significant, *=p<0.05, ***=p<0.0005). 
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4.2.7 SHANK3 does not alter internalization of sst2 
As we hypothesized that SHANK3 plays a role in sst2 trafficking, we asked if 
SHANK3 would alter the rate or extent of internalization of sst2 after stimulation with 
agonist. We transfected cells with sst2 and SHANK3 or an empty GFP vector as a 
control. Transfections were titrated to have the same amount of SHANK3 and GFP 
but to match sst2 surface expression. We used a cell surface ELISA to measure 
both the rate and extent of sst2 internalization after stimulation with SS14 and found 
no difference in either (Fig 22A). This indicates that SHANK3 is not tethering the 
receptor at the membrane and increasing cell surface expression in that manner. We 
also tested if the PDZ domain of SHANK3 alone had an effect on the extent of sst2 
internalization (Fig 22B). We did not find an effect, which is consistent with our data 
indicating that the PDZ domain of SHANK3 does not alter surface expression and 
the full length SHANK3 protein does not alter the rate or extent of internalization of 
sst2. 
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Figure 22: Overexpression of SHANK3 does not alter sst2 internalization. A) 
HEK293 cells were transiently transfected with sst2 and either an empty GFP vector 
or GFP-SHANK3. Cells were treated with SS14 (100nM) for the times indicated and 
receptor cell surface expression was determined by ELISA. Data are the mean ± 
SEM of three independent experiments. There is no difference in the rate or extent 
of internalization between the control and SHANK3 overexpression groups as 
determined by sum of squares F-test. B) HEK293 cells were co-transfected with sst2 
and a clone only expressing the PDZ domain of SHANK3 or an empty vector as a 
control. Cells were treated with SS14 (100nM) for 30min and cell surface expression 
was determined by ELISA and compared to untreated cells. (n.s. = not significant) 
 
4.2.8 The SAM domain alters subcellular localization of SHANK3 
We sought to further understand how SHANK3 alters sst2 surface 
expression. We began by determining the subcellular localization of the full length 
SHANK3 constructs versus the two truncation mutants. We found that both the 
truncation mutants were localized in the nucleus where the full-length SHANK3 
construct clustered in cytoplasmic puncta. This is consistent with the literature 
however it is not know what vesicles full length SHANK3 is localized in. Importantly, 
none of the SHANK3 constructs are localized at the plasma membrane at steady 
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state indicating that SHANK3 likely plays a role in sst2 anterograde or retrograde 
trafficking versus playing a role in stabilizing the receptor at the membrane. 
 
 
 
 
Figure 23. Localization of SHANK truncation mutants. GFP tagged SHANK 
truncation mutants were co-transfected with sst2 into HEK293and stained for 
immunofluorescence. Cells were imaged by widefield fluorescence imaging with a 
40x objective. 
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4.2.9 Rat pituitary expresses alternative isoforms of SHANK3 
Given that only the full-length isoform of SHANK3 increased cell surface 
expression of sst2 and not the truncation mutants, we asked if the full length 
SHANK3 isoform was present in pituitary tissue by western blot. We used two 
different commercially available antibodies that detect various regions of SHANK3. 
The first is targeted towards the N-terminal and detects the SH3 and PDZ domains. 
The second antibody detects the C-terminal region and was raised against a large 
portion of the proline-rich region. Rat cortex and pituitary were harvested from 
Sprague Dawley rats to determine SHANK protein expression. A SHANK2 antibody 
was used as a control, as whole rat pituitary extracts have been shown to express 
SHANK2. Interesting, we found a different pattern of expression in the three protein 
extracts using the N-terminal and C-terminal SHANK3 antibodies indicating that 
there are multiple protein isoforms of SHANK3 present in the pituitary. Additionally, 
the pattern of expression differs from that of the cortex and from GH4C1 cells, a rat 
somatotroph cell line. This finding is of particular significance given that the full-
length isoform of SHANK3 was required to increase cell surface expression of sst2. 
 
 
 
 
 
Figure 24: SHANK3 expression in rat cortex, pituitary, and GH4C1 cells. A) Rat 
cortex, rat pituitary, and GH4C1 lysates were probed for SHANK3 expression using 
two different antibodies. The N-terminal SHANK3 antibody targets the PDZ domain 
and the C-terminal SHANK3 antibody was raised to a portion of the proline-rich 
region. Lysates were also probed for SHANK2 using an antibody targeting the PDZ 
domain. B) Specificity of SHANK antibodies. HEK293 cells were transfected with 
GFP tagged SHANK1, SHANK2, or SHANK3 clones and probed with the antibodies 
listed. 
 
	   93	  
 
 
 
250$%
150$%
100$%
75$%
50$%
SHANK3
N-terminal 
SHANK3
C-terminal 
SHANK2
Co
rte
x
Co
rte
x
Pi
tu
ita
ry
 
GH
4C
1
250$%
150$%
250$%
150$%
250$%
150$%
250$%
150$%
250$%
150$%
G
FP
-S
HA
NK
1
G
FP
-S
HA
NK
2
G
FP
-S
HA
NK
3
G
FP
SHANK1
SHANK2
SHANK3
N-terminal
SHANK3
C-terminal
GFP
GAPDH
A
B
Pi
tu
ita
ry
 
G
H4
C 1
Co
rte
x
Pi
tu
ita
ry
 
G
H4
C 1
	   94	  
4.3 Discussion 
SHANK1 and SHANK2 have been shown to bind to sst2 through their PDZ 
domains(88-90). They were initially identified as sst2 binding proteins using a yeast-
2-hybrid screen with the C-terminal of sst2 as bait and a human brain cDNA library. 
Although the group that identified these binding partners were not able to find a 
function for this protein-protein binding, they concluded that SHANK2 is recruited to 
the plasma membrane in sst2 expressing cells after stimulation with SS14(90). We 
were able to show that SHANK3 also interacts with sst2 through a PDZ ligand-
domain interaction. It is possible that sst2 interacts with SHANK3 indirectly as well 
although we were not able to determine this. Other receptors, such as mGluR5, can 
interact with SHANK3 both directly through a PDZ ligand-domain interaction and 
indirectly through binding to cortactin(166).  
It is likely that SHANK1, SHANK2, and SHANK3 have different effects on sst2 
regulation and signaling, allowing sst2 to exert context specific effects. Interestingly, 
SHANK2 and SHANK3 were also identified in rat pituitary cells, specifically 
somatotrophs where sst2 is also highly expressed, indicating that SHANK proteins 
likely play a role in sst2 regulation in the pituitary(145). An important outstanding 
question is which isoforms of SHANK2 and SHANK3 are present in the pituitary, as 
this would determine both the possibility for these proteins to interact with sst2 in a 
PDZ dependent manner, and would affect the specific regulatory effects they had on 
sst2. Of note, we determined that SHANK expression varies between rat and human 
and while SHANK2 and SHANK3 are expressed in rat pituitary, SHANK1 and 
SHANK3 are present in human pituitary tissue. Importantly, we determined that the 
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expression of SHANK proteins varies between normal tissue and neuroendocrine 
tumors. Both secretory and non-functioning pituitary tumors lost or gained various 
SHANK proteins. The potential effects on sst2 regulation and signaling are 
numerous and much work needs to be done to understand the functional effects of 
the three different SHANK family members on sst2. 
 How PDZ proteins influence sst2 regulation, trafficking, and signaling is an 
important and outstanding question. Before we began this study, SHANK1 and 
SHANK2 had been shown to bind to sst2 through a PDZ ligand-domain interaction, 
however nothing was known about the functional role of this binding. Co-expression 
of full length SHANK3 and sst2 leads to increased cell surface expression of sst2. 
This effect required the full-length isoform of SHANK3 and was abolished when the 
SAM domain of SHANK3 was removed. This difference is likely due to the nuclear 
localization of the SHANK3 isoforms lacking a SAM domain, they likely cannot 
interact with sst2 in either the cytoplasm or at the plasma membrane. The 
mechanism through which SHANK3 alters sst2 surface expression is an outstanding 
question. We hypothesize that SHANK3 increases surface expression through 
regulating anterograde trafficking of sst2. We found that SHANK3 expression did not 
alter the rate or extent of sst2 internalization. Additionally, sst2 is stable at the cell 
membrane in the absence of agonist and SHANK3 is found in discrete vesicles at 
steady state. This indicates that SHANK3 is not altering either agonist driven or 
constitutive internalization pointing to a role for SHANK3 in anterograde transport of 
sst2 to the cell membrane. Overall, our data indicates an important role for SHANK3 
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in cell surface expression of sst2 in neuroendocrine tissues and tumors likely playing 
an important role in tumor response to octreotide. 
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Chapter 5 
Discussion and Future Directions 
 
5.1 Somatostatin Analogs and Neuroendocrine Tumors 
Understanding how sst2 exerts its effects in cells is crucial to not only 
understand its physiological role but also its role in the treatment of neuroendocrine 
tumors. Somatostatin analogs have been an effective tool for the diagnosis and 
treatment of NETs. First, SAs are the most effective treatment available to treat 
hormone hyper-secretion from a wide variety of tumor types. Hormone secretion can 
cause problems that range from uncomfortable to debilitating to deadly(23). 
Activation of sst2 in these tumor types leads to a decrease in cAMP and to the 
activation of potassium and calcium channels to decrease acute hormone 
secretion(1). Secondly, SAs have been shown to control tumor growth. While 
numerous reports showing the inhibition of tumor growth have been described since 
the clinical introduction of octreotide, only recently do we have robust clinical data 
demonstrating this effect independent from the effects on hormone secretion(44, 
61). Additionally, the anti-secretion and anti-tumor effects are not always linked even 
in functional NETs. This indicates that the pathways that sst2 regulates for hormone 
secretion and those governing tumor growth are distinct in certain cell populations. 
Thirdly, radiolabeled SAs are used to both to both identify and ablate NETs. Given 
the wide clinical use of SAs, understanding cell type specific effects of sst2 has 
become increasingly important(50). While the mechanism leading to an acute 
decrease in hormone secretion has been well described, the mechanisms governing 
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long-term reductions in hormone synthesis, tumor growth, and drug resistance are 
all still poorly understood. As there are limited additional treatment options for NETs, 
especially to control hormone hyper-secretion, increasing our understanding of how 
sst2 exerts its function is an important clinical and basic science question. 
Perhaps the most important outstanding question is the mechanism 
governing NET resistance to SAs. There are two general patterns of resistance to 
SAs seen in NET. Pituitary tumors, particularly GH-secreting tumors, tend to either 
initially respond or are resistance to SAs. This differs from the pattern seen in GI and 
pancreatic NETs that tend to lose their response over time(16). While many 
hypotheses have been developed to explain tumor resistance to SAs, none can fully 
explain tumor resistance. Originally it was thought that resistance tumors must lack 
expression of sst2, however this turned out not to be the case. As sequencing 
methods improved, others looked into the possibility of mutations within the receptor 
leading to a lack of drug response. This turned out to be relatively uncommon and 
could not account for almost 50% of pituitary tumors not responding to SAs. Given 
that neither loss of the receptor nor mutations account for the resistance to SAs 
observed in pituitary tumors, the current hypothesis is that sst2 cannot engage with 
its downstream machinery to exert its anti-secretion effects(2). Numerous reports 
exist showing a decrease in hormone secretion without an anti-tumor effect and 
more recently SAs have been used in non-secretory NETs. The combination of 
clinical and basic science data indicates that sst2 exerts cell type specific effects 
through numerous pathways that have yet to be fully described. Understanding 
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these different pathways is crucial for to understand the different effects seen in both 
different tumor types and within the same tumor type.  
 
5.2 Sst2 Trafficking and Signaling 
GPCRs use numerous mechanisms to exert cell specific effects even while 
acting on common pathways. One mechanism that has been shown to be 
increasingly important not only for GPCRs but numerous receptors, ion channels, 
kinases, and other proteins is specific spatial-temporal signaling. GPCRs can act in 
protein complexes at specific times and cellular locations after activation to generate 
highly specific signals. These signals depend both on a receptor’s ability to bind to 
and interact with specific protein complexes and to be on the correct intracellular 
pathway. PDZ ligands are highly flexible protein-protein binding domains allowing for 
receptors to bind to numerous PDZ domain-containing proteins. Many of these PDZ 
domain-containing proteins are large scaffolding proteins that allow for the 
development of large protein complexes. Before this study, there were three known 
PDZ binding partners for sst2, however nothing was known about the function of the 
sst2 PDZ ligand.  
While there are numerous outstanding questions about the role of PDZ 
ligand-domain interactions in the regulation of sst2, we have shown that the PDZ 
ligand acts as a crucial intracellular trafficking signal, governing the specific route 
that sst2 takes through the cell. Sst2 requires a specific set of protein-protein binding 
partners to traffic through the cell and uses alternative routes to return to the cell 
surface if those binding partners are disrupted. Interestingly, sst2 does not need a 
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PDZ ligand or its 10 C-terminal amino acids to efficiently recycle to the plasma 
membrane after internalization but we have found that the C-terminal mutants can 
access different recycling pathways.   
An important outstanding question is why sst2 can access these different 
pathways. One potential explanation is various recycling pathways are necessary to 
exert specific signaling effects. For example, PTHR1 can recycle through both a 
slower recycling pathway through the TGN and a rapid recycling pathway. The rapid 
recycling pathway is necessary for PTHR1 to exert its effects on bone 
development(74, 161). While signaling through Gi/o proteins is well described for 
sst2, it is likely that sst2 affects a range of other signaling pathways that have yet to 
be described. Further characterization of these pathways is going to be necessary 
before understanding the potential signaling effects. Whether sst2 signals 
intracellularly is another outstanding question. Receptors can signal both at the 
plasma membrane and from endosomes through both G-proteins and other 
signaling pathways such as β-arrestin(170). Teasing out membrane signaling from 
intracellular signaling is a difficult task given the burst of signaling that is generated 
at the plasma membrane versus the more subtle signaling that occurs along the 
intracellular trafficking pathway. This requires a careful selection of the signaling 
output used along with a specific assay design to distinguish the location of signal 
generation. Common outputs used to gauge intracellular signaling for GPCRs 
include cAMP accumulation and ERK phosphorylation as these tend to be easy to 
measure and have been demonstrated to be generated both at the membrane and 
from endosomes for GPCRs. Sst2’s role as an inhibitory receptor adds a significant 
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challenge to studying and understanding the receptor’s signaling. This requires 
interpretation of both the dynamics of the stimulant and sst2’s inhibitory effect 
making determining the location of signaling more difficult.  
Another potential explanation for sst2’s ability to access different recycling 
pathways is to allow for a population of receptors to undergo resensitization. This 
pathway could be crucial for receptors to be fully functional after returning to the 
plasma membrane. Numerous additional questions remain such as which trafficking 
proteins are sorting sst2 into these various pathways and are modifications to sst2 
required.  
 
5.3 SHANK protein regulation of sst2 	   How SHANK proteins affect the trafficking, signaling, and regulation of sst2 is 
still an important and outstanding question. We were able to confirm that the PDZ 
domains of SHANK1 and SHANK2 can bind to sst2 and we showed that sst2 binds 
to the SHANK3 PDZ domain as well. We were also able to show that SHANK3 
expression increases cell surface expression of sst2. Interestingly this requires the 
full-length isoform of SHANK3 but is not dependent on the PDZ ligand of sst2. Both 
the mechanism of the effect and why it is PDZ ligand independent are both 
interesting and worthwhile questions to pursue in the future. We hypothesize that 
SHANK3 could be acting at one of several different steps of sst2 regulation. The first 
possibility is that SHANK3 could be altering sst2 anterograde trafficking. SHANK3 
could act as a chaperone from the endoplasmic reticulum or the trans-golgi network 
to help shuttle sst2 to the membrane. It could also potentially affect endosomal 
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dynamics allowing for greater numbers of sst2 receptors to reach the plasma 
membrane. Another possibility is that SHANK3 helps stabilize sst2 at the plasma 
membrane or inhibits constitutive internalization. This possibility is less likely given 
that SHANK3 is not located at the plasma membrane at steady state. Additionally, 
sst2 is stable at the membrane in the absence of ligand. The final possibility is that 
SHANK3 alters sst2 recycling to allow for more receptors to return to the plasma 
membrane. As sst2 recycles almost fully and the increase in cell surface receptor is 
seen at steady state, an alteration in recycling is less likely. Going through these 
various possibilities lead us to hypothesize that SHANK3 is most likely playing a role 
in anterograde trafficking. As little is known about sst2’s anterograde trafficking, 
much work will need to be done to understand which proteins are involved in the 
export of sst2 to the plasma membrane and how SHANK3 is involved in this 
process. 
 Our data also indicates that the full-length isoform of SHANK3 is required for 
increased sst2 cell surface expression. This leads to the question of how the other 
two SHANK proteins, SHANK1 and SHANK2, regulate sst2 and if the various 
isoforms play different roles in sst2 trafficking, signaling, and regulation. 
Interestingly, we did not find that the full-length isoform of SHANK3 is expressed in 
the pituitary. However, SHANK2 and SHANK3 have been shown to be expressed in 
somatolactotrophes and we found that additional shorter bands were detected in the 
pituitary by western blot(145). A future experiment would be to characterize the 
isoforms present in the pituitary either by rapid amplification of cDNA ends (5’ 
RACE) or another method. Understanding which isoforms are present in the pituitary 
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is crucial to then understand how these various isoforms interact with sst2 and what 
their role in sst2 regulation may be. Additionally, it would be worthwhile to 
understand how the interactions of sst2 and SHANK proteins affect sst2 localization 
and the synapse and sst2 modulation of neuronal signaling. Overall, there is a great 
deal of work left to be done to understand the interaction between sst2 and the 
various SHANK proteins. 
 
5.4 Summary 	   Sst2 plays a crucial role in the treatment of neuroendocrine tumors and 
overcoming resistance to somatostatin analogs will be a large clinical advance. 
Understanding how sst2 exerts cell and context specific effects will allow us to better 
understand tumor responses to somatostatin analogs. Before this study, little was 
known about the intracellular trafficking of sst2 and the motifs that regulate that 
trafficking. We have shown that sst2 traffics from early to late endosomes, and is 
sorted in a retromer dependent manner from the late endosome to the TGN. We 
have also shown that sst2 can recycle to the plasma membrane through multiple 
different pathways depending upon its ability to bind to sorting proteins through 
binding either the last three or ten amino acids of the C-terminal tail. We have shown 
the SHANK3, a PDZ domain protein, can increase surface expression of sst2. 
Despite these discoveries, numerous questions remain. More studies will need to be 
done to understand which proteins are involved in sorting sst2 at each step and what 
the consequences of undergoing sequence dependent sorting is for sst2. 
Additionally, numerous questions remain as to how the SHANK family of proteins 
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interacts with and affects sst2 regulation. Better understanding these interactions will 
help us to understand the consequences of altered expression of SHANK proteins 
and other sst2 interacting proteins in tumor cells. Addressing these questions and 
continuing to elucidate mechanisms of sst2 regulation will allow us to improve 
treatments for NETs in the future. 
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